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1. Summary 
B-Chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of 
apoptotic resistant CD5+ B lymphocytes. There is an increased secretion of Wnt ligands 
indicating an autocrine loop leading to the extended survival of B-CLL cells. Lymphoid 
enhancer factor 1 (LEF-1) is a potent transcription factor regulating the expression of several 
Wnt induced target genes. A comprehensive gene expression profiling from two independent 
studies revealed that LEF-1 mRNA was ~3000 fold overexpressed in B-CLL when compared 
to its healthy counterpart. 
The objective of this present study is to demonstrate the therapeutic benefit of 
inhibiting LEF-1 expression in B-CLL cells using novel small molecule inhibitors 
CGP049090 and PKF115-584 in vivo and in vitro. In order to explore the anti-leukemic 
potential of CGP049090 and PKF115-584 we tested its effects on freshly isolated B-CLL 
cells, prolymphocytic cell line (JVM-3 & MEC-1) and in a subcutaneous mouse xenograft 
model. 
The present study shows that, in freshly isolated B-CLL cells there was high protein 
expression and nuclear localization of LEF-1 and β-catenin indicating active LEF-1 mediated 
transcription whereas LEF-1 remained undetectable in healthy B cells. Preliminary 
experiments of LEF-1 inhibition using siRNAs resulted in increased apoptosis indicating 
LEF-1 plays an important role in the survival of B-CLL cells. This observation was extended 
using CGP049090 and PKF-115584 as they induce dose dependent cytotoxicity in B-CLL, 
whereas the healthy B cells are not significantly affected. The half maximal inhibitory 
concentration (IC50) was less than 1 µM in primary B-CLL cells and cell lines whereas it was 
more than 5 µM in healthy B cells. CGP049090 and PKF-115584 induced apoptotic cell death 
in primary B-CLL cells and cell lines by cleavage of caspases 8, 9, 3 and 7 and subsequent 
cleavage of Poly (adenosine diphospate-ribose) polymerase (PARP). Both inhibitors also 
altered the expression of several anti-apoptotic proteins like X-linked Inhibitor of Apoptosis 
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Protein (XIAP), Mantle cell lymphoma-1 (Mcl-1) and B cell lymphoma-2 (Bcl-2). Co-
Immunoprecipitation experiments revealed that both the inhibitors effectively disrupt the β-
catenin/LEF-1 interaction, resulting in the down regulation of LEF-1 target genes such c-myc, 
cyclin D1 and LEF-1. Furthermore, when the inhibitors were tested in an in vivo JVM-3 
subcutaneous xenograft nude mouse model, more than 70% inhibition of tumor growth and an 
increase in the median survival of the treated group without leading to systemic toxicity was 
observed. Immunohistochemistry analysis of the tumor sections revealed LEF-1 down 
regulation and subsequent inhibition of proliferation by down regulation of Proliferating Cell 
Nuclear Antigen (PCNA) and increase in apoptosis (cleaved PARP). 
In summary, the data showed that LEF-1 is a potential therapeutic target in the 
treatment of B-CLL. Both CGP049090 and PKF115-584 showed potent inhibitory effects on 
the survival of CLL cells in vitro and in vivo without affecting the healthy cells. Both 
CGP049090 and PKF115-584 are hence, potential anti-cancer agents in B-CLL and other 
neoplastic malignancies with aberrant LEF-1/ T cell factor (TCF) transcriptional activity. 
Further investigations are warranted to determine the feasibility of these small molecules for 
therapeutic approach in humans. 
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2. Zusammenfassung 
Die chronische lymphatische B-Zell Leukämie (B-CLL) ist durch eine Akkumulation 
von apoptose-resistenten CD5-positive B-Lymphozyten charakerisiert. In letzter Zeit wurden 
verschiedene Faktoren beschrieben, welche zu einer aberranten Aktivierung der Wnt-
Signalkaskade in B-CLL Zellen beitragen. Eine vermehrte Sekretion von Wnt-Liganden weist 
auf einen autokrinen Rückkopplungsmechanismus hin, welcher eine Rolle im gesteigerten 
Überleben der B-CLL Zellen spielt. 
LEF-1 ist ein potenter Transkriptionsfaktor, welcher die Expression verschiedener 
Wnt-induzierter Zielgene reguliert. LEF-1 wurde in zwei unabhängigen 
Genexpressionsanalysestudien als Gen mit etwa 3000-facher Überexpression in der B-CLL, 
relativ zum Expressionslevel in gesunden B-Zellen, beschrieben. Der Transkriptionsfaktor 
LEF-1 ist damit exklusiv auf B-CLL Zellen exprimiert. 
Das Ziel der vorliegenden Studie ist es, den therapeutischen Nutzen einer gezielten 
Inhibierung von LEF-1 in B-CLL Zellen, durch die Verwendung zweier sogenannter „small 
molecule“ Inihibitoren CGP049090 and PKF115-584, sowohl in vivo als auch in vitro zu 
zeigen.  
Um den anti-leukämischen Effekt dieser Substanzen zu zeigen, wurden deren Effekte 
auf frisch isolierte B-CLL Zellen und prolymphozytischen Zelllinien ((JVM-3 & MEC-1) 
untersucht. Zudem wurden beide Substanzen auf Ihre Wirksamkeit in einem JVM3-Xenograft 
Mausmodel getestet.  
In frischen B-CLL Zellen konnten wir große Proteinmengen von LEF-1 detektieren, 
welche größtenteils im Zellkern zu finden waren. Auch β-Catenin war vorrangig im Zellkern 
vorhanden, was darauf schließen lässt, dass LEF-1 in B-CLL Zellen transkriptionell aktiv ist. 
LEF-1-Protein war in gesunden B-Zellen nicht detektierbar. Eine Runterregulierung von 
LEF1 mittels siRNA hat zu einem vermehrten Zellsterben durch Apoptoseinduktion geführt, 
welches die wichtige Funktion von LEF-1 für das Überleben der B-CLL Zelle zeigt. Diese 
Zusammenfassung 
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Beobachtung wurde dadurch erweitert, dass auch CGO049090 und PKF-115584 sowohl zeit- 
als auch konzentrationsabhängig zytotoxisch auf B-CLL Zellen wirken, während gesunde B-
Zellen in signifikant geringerem Maße betroffen sind. Die IC50 in primären B-CLL Zellen 
war <1 µM und >5 µM in gesunden B-Zellen. CGO049090 und PKF-115584 führten zu 
apoptotischem Zelltod durch eine Spaltung der Caspasen 8, 9, 3 und 7 und eine 
darauffolgende Spaltung von poly (adenosine diphospate-ribose) polymerase (PARP). Beide 
Inhibitoren führten zudem zu einer veränderten Expression verschiedener antiapoptotischer 
Proteine wie X-linked Inhibitor of Apoptosis Protein (XIAP), Mantle cell lymphoma-1 (Mcl-
1) und B cell lymphoma-2 (Bcl-2). Co-Immunoprezipitationsexperimente zeigten, dass beide 
Inhibitoren effektiv den β-Catenin/LEF-1 Komplex trennen, was zur Herunterregulation der 
LEF-1 Zielgene c-myc, cyclin D1 und LEF-1 führt. Darüber hinaus wurden beide Inhibitoren 
in einem subkutanen JVM-3-Xenograft Nacktmausmodel getestet und erzielten eine 
Tumorinhibitionsrate von >70%. Zudem erhöhte sich die mittlere Überlebensrate der Mäuse 
durch die Behandlung ohne erkennbare systemisch toxische Effekte. Eine 
Gewebeuntersuchung der Tumore ergab eine Herunterregulation von LEF-1 und eine 
darausfolgende Herunterregulation des Proliferating Cell Nuclear Antigens (PCNA), welches 
auf eine erniedrigte Proliferationsrate hinweist. Zudem wurde eine verstärkte Aktivität von 
PARP detektiert, wodurch auf eine erhöhte Apoptoseinduktion im Tumorgewebe behandelter 
Mäuse geschlossen werden kann.  
Zusammenfassend lässt sich sagen, dass LEF-1 einen potentiellen therapeutischen 
Ansatzpunkt in der B-CLL darstellt. Die beiden Substanzen CGP049090 and PKF115-584 
weisen eine hohe Wirksamkeit bei der Zelltodinduktion B-CLL Zellen gegenüber auf, 
während sie gesunde B-Zellen kaum beeinträchtigen. CGP049090 and PKF115-584 eignen 
sich deshalb als potentielle Substanzen in der B-CLL Therapie und auch in anderen 
neoplastischen Erkrankungen, die eine aberrierende transkriptionelle Aktivität von LEF-
Zusammenfassung 
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1/TCF aufweisen. Weitere Untersuchungen sind wünschenswert um die Anwendbarkeit dieser 
zwei Substanzen für therapeutische Zwecke im Menschen genauer zu bestimmen. 
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3. Introduction 
During normal lymphocyte differentiation B cells jeopardize their genomic integrity 
through the formation and revision of their antigen receptors. A second potentially dangerous 
event is the response to antigens, which under normal circumstances, is a tight homeostatic 
regulation of clonal expansion of B cells. A compromise in either of the two events would 
result in oncogenic genomic hits that block differentiation, prevent apoptosis and/ or promote 
proliferation leading to several types of lymphoma and leukemia. B-Chronic lymphocytic 
leukemia (B-CLL) is one such disease which results due to a prolonged and unregulated 
antigenic stimulation contributing to clonal expansion of leukemic B cells. 
3.1. Hematopoiesis 
To comprehend the origin of B-CLL we have to understand the mechanism of 
generation of different cell types of the lymphoid and myeloid systems (Figure 1). All the 
mature blood cells in the body are generated from a relatively small number of hematopoietic 
stem cells (HSCs) and progenitors (Weissman 2000). In the mouse, a single HSC can 
reconstitute the entire hematopoietic system for the natural lifespan of the animal (Osawa 
1996). HSCs generate the multiple hematopoietic lineages through a series of intermediate 
progenitors. Those are the common lymphoid progenitors (CLPs) that give rise to natural 
killer cells (NK), T cells, and B cells, and the common myeloid progenitors (CMPs), which 
can generate monocytes, granulocytes, megakaryocytes, and erythrocytes (Kondo 1997; 
Akashi 2000). Out of the CMPs develop more specialized progenitors, that are further 
restricted to a number and type of cell lineages that they can generate. These are the 
granulocyte/monocyte progenitors (GMP), which give raise to the granulocytes and 
monocytes, and the megacarythrocyte/erythrocyte progenitors (MEP), which can develop to 
megakaryocytes and erythrocytes (Akashi 2000). The terminally differentiated cells produced 
cannot divide any longer and undergo apoptosis after days to decades depending on their cell 
type. 
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During the process of B cell differentiation the B cells generate the B cell receptors 
(BCRs) by V(D)J recombination involving double strand DNA breaks initiated by 
recombination activated genes (RAG1 and RAG2) that are resolved by the non-homologus 
end joining repair apparatus (Fugmann et al. 2000). In this process, the cells are often 
susceptible to chromosomal translocations replacing the usual regulatory sequences of a gene 
with heterologous regulatory elements which lead to inappropriate gene expression at the 
breakpoints, leading to lymphomas (Pelicci et al. 1986). 
Figure 1: Hematopoiesis 
Long term hematopoietic stem cells (LT-HSC) give rise to short term (ST) HSCs. Due to 
different stimuli they either become common lymphoid progenitors (CLP) or common 
myeloid progenitors (CMP). Downstream of CLPs the cells either develop to natural 
killer cells (NK), to B or T cells. The CMPs give rise to more specialized progenitors, 
granulocyte/monocyte progenitors (GMP) and megakaryocyte/erythrocyte progenitors 
(MEP), which finally differentiate to granulocytes, monocytes, megakaryocytes and 
erythrocytes. 
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On the other hand when a differentiated but naïve B cell encounters an antigen, the 
naïve B cell gets activated and interacts with follicular dendritic cells, T cells and the antigen 
within the microenvironment of the Germinal Centre (GC). Here the B cell undergoes Class 
Switch Recombination (CSR) via DNA breaks and extensive remodeling of the DNA and 
somatic hypermutation (SHM) using point mutations of the immunoglobulin genes. This 
again makes the B cell genome prone to genetic alterations leading to gross chromosomal 
mutations (Boehm et al. 1989; Honjo et al. 2002). 
Interestingly, B-CLL does not represent any of these typical gross chromosomal 
translocations generated by the above mechanisms (Montserrat & Rozman 1995), but 
represent in two distinct subtypes i.e. B-CLL cells which have undergone SHM (IgVH 
mutated) in the germinal centre and those cells which did not undergo SHM (IgVH 
unmutated) (Shaffer et al. 2002). Hence the origin of this disease is still a mystery. The 
current hypothesis favors the role of an antigen in the pathogenesis of B-CLL. 
3.2. The Role of Antigens in B-CLL 
The role of antigens have been implicated in some lymphomas such as Marginal Zone 
Lymphoma (MALT) where the 70% of the patients present an infection with helicobacter 
pylori leading to gastric ulcers (Wotherspoon et al. 1993; Wotherspoon et al. 1994). 
Helicobacter pylori  specific T cells stimulate the proliferation of MALT lymphoma cells in 
culture and these patients can be cured of their MALT simply by antibiotics (Hussell et al. 
1993). 
Several gene expression studies have been carried out in determining the difference 
between the IgVH unmutated and IgVH mutated forms of B-CLL (Rosenwald et al. 2001; 
Klein et al. 2001). These evidences indicate a potential role of an antigen in the clonal 
expansion of B-CLL cells. CLL B cells use a biased VH repertoire and have non-random 
combinations of V, D and J segments that are not characteristic of normal blood B cells. 
Furthermore, certain VH genes are used differentially by immunoglobulin-unmutated and -
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mutated forms of CLL. For example, the VH1-69 gene is associated almost exclusively with 
immunoglobulin-unmutated CLL, whereas other VH genes, such as VH4-34, VH1-07 and 
VH3-21, are over-represented in immunoglobulin-mutated CLL, indicating role of antigen in 
the expansion of these cells (Damle et al. 1999; Fais et al. 1998; Tobin et al. 2002;). However 
the nature of this antigen is still unknown, it is predicted that it is presumably auto antigens 
such as single- and double-stranded DNA, and IgG. (Sthoeger et al. 1989; Borche et al. 1990). 
3.3. Biology of chronic lymphocytic leukemia 
The ability of one cell to influence the behavior of another cell is achieved through cell 
communication, termed cell signaling. Over the time several different signaling pathways 
have been developed, as for example the Notch-, the Phosphatidylinositol-3 kinase (PI3K), 
the BMP-, and the Wnt signaling pathway which are crucial in early development and 
maintenance of the cells. At the end of each intracellular signaling pathway are target 
proteins, which when altered changes the behavior of the cell. Moreover, a crosstalk between 
the different pathways occurs, which leads to a big network of signals and a tight regulation 
within a cell. Disturbance of the balanced systems often leads to diseases, as for example 
cancer. B-CLL is such a condition wherein there is a deregulation of several signaling 
pathways, which leads to extended survival. We will discuss some of the important signaling 
defects in the pathogenesis of CLL but will mainly focus on the role of Wnt signaling 
pathway in B cell development and pathogenesis of CLL. Figure 2 shows an overview of the 
pathogenesis of B-CLL during early stages of differentiation and junctures where additional 
oncogenic hits/antigenic stimulation might occur resulting in its activation of variety of 
pathways involved in prolonged survival (Shaffer et al. 2002). 
Signaling defects in CLL is considered to be one of the factors prolonging the survival 
of the B cells than the normal lymphocytes (Hamblin & Oscier 1997). The BCR signaling is 
important in determining the B-cell fate, and the level of BCR engagement is modulated by 
the antigenic valency, epitope density and epitope organization. Upon BCR engagement, 
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receptor aggregation induces phosphorylation of the immunoreceptor tyrosine-based 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: An overview of the pathogenesis of B-CLL (Adapted from A. L. Shaffer 2002) 
The two subtypes of chronic lymphocytic leukemia (CLL) — immunoglobulin-mutated and 
immunoglobulin-unmutated CLL — are distinguished by the presence or absence of 
immunoglobulin variable (V)-region mutations, by differences in gene expression and by 
their clinical courses. This model emphasizes the potential role of antigenic stimulation in 
the progression of this disease. Immunoglobulin-unmutated and -mutated forms have a 
different repertoire of heavy-chain V-region (VH) gene rearrangements, which indicates 
that the type of CLL that results is dictated by the specificity of the B-cell receptor (BCR). 
Many studies have implicated an antigen or autoantigen indirectly in the pathogenesis of 
CLL. Antigenic stimulation might occur before and/or after the B cell acquires a genetic 
change (oncogenic hit) and becomes a CLL cell. It is also possible that early stages of 
CLL occur without oncogenic hits to the B cell. Immunoglobulin-unmutated CLL most 
probably originates from a pre-germinal centre (pre-GC) B cell. Immunoglobulin-mutated 
CLL might originate from a post-GC B cell. Alternatively, immunoglobulin-mutated CLL 
might originate from a pre-GC B cell that is nevertheless driven by antigen through a GC 
reaction. The clinical manifestations of CLL might be related to whether antigen drives 
continued clonal expansion or induces an anergic state. Disease progression might be 
influenced by the accumulation of additional oncogenic hits. 
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activation motifs (ITAMs) by Src-family tyrosine kinases (Pierce 2002). This leads to 
recruitment of other kinases triggering activation of intracellular signaling cascades. Low 
expression of BCR is the hallmark of CLL (Payelle-Brogard et al. 2002; Vuillier et al. 2005) 
and its stimulation is considered to be important for survival and proliferation of CLL 
(Stevenson & Caligaris-Cappio 2004). 
PI3K and mitogen activated protein kinases (MAPK) are activated through membrane 
receptor tyrosine kinases and are involved in several signal transduction pathways in B cells 
such as CD40 signaling, BCR signaling and signaling of variety of cytokines (Ringshausen et 
al. 2002). Studies have shown the constitutive activation of these pathways in CLL cells and 
their requirement in the maintenance of CLL viability (Ringshausen et al. 2004; Longo et al. 
2007; Plate 2004).  
Failed programmed cell death or apoptosis is a characteristic feature of CLL (Reed 
1998). The Bcl-2 family members (bcl-2 bax, bclxL) are over-expressed in CLL (Hanada et 
al. 1993). The imbalance in the ratio of major pro- and anti- apoptotic family proteins is 
associated with the treatment response of CLL (Kitada et al. 1998; Pepper et al. 2001). Mcl-1, 
another anti-apoptotic protein is also overexpressed in CLL cells and contributes to failure of 
cytotoxic therapy (Kitada et al. 1998; Saxena et al. 2004). There is also evidence that indicate 
Mcl-1, Bcl-xL and XIAP are regulated by Akt and Erk pathway but only Mcl-1 is essential for 
CLL survival (Longo et al. 2008). 
Most recently great emphasis is being placed on the role of aberrant Wnt signaling in 
malignant diseases and the different mechanisms, major players of Wnt signaling and its role 
in B cell development will now be elaborated further. 
3.3.1. Overview of Wnt signaling mechanism 
 
The Wnt signaling consists of three different pathways. The classical Wnt/β-catenin 
pathway, termed canonical Wnt pathway, the frizzled regulated planar cell polarity pathway 
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(PCP), and the Wnt/Ca2+ pathway (Kuhl et al. 2000; Wang & Malbon 2003). The PCP 
pathway involves the small GTPases - rho and cdc42 as well as the Jun N-terminal kinase 
(JNK) (Weber et al. 2000) and regulates Drosophila development independently of β-catenin 
(Tree et al. 2002). The mechanism is not completely understood, but it seems that it is not a 
linear signaling pathway from the receptor frizzled (Fzd) through a downstream cytoplasmic 
protein Dishevelled (Dsh), to tissue specific proteins, but that the signaling involves 
asymmetric distribution of Fzd and Dsh and this pathway is functioning through a feedback 
loop (Tree et al. 2002). 
In the Wnt/Ca2+ pathway, Fzd appears to act through heterotrimeric guanine 
nucleotide-binding proteins (G proteins) (Slusarski et al. 1997) and seems to activate 
phospholipase C (PLC) and phosphodiesterase (PDE) (Ahumada et al. 2002), which lead to 
increased concentrations of free intracellular calcium and to decreased intracellular 
concentrations of cyclic guanosine monophosphate (cGMP). 
The canonical Wnt cascade plays a critical role in many developmental processes. It 
has been implicated in the development of B and T cells (Okamura et al. 1998; Reya et al. 
2000) and in the self-renewal of hematopoietic stem cells (HSC) (Reya et al. 2003). The 
transcription factors LEF/TCF mediate a nuclear response to Wnt signals by interacting with 
β-catenin. Following a Wnt signal, β-catenin is stabilized and transported to the nucleus, and 
is binding to the LEF/TCF proteins to turn on target genes.  
3.3.2. Molecular Mechanism of Canonical Wnt signaling 
 
A schematic overview of the canonical Wnt signaling pathway in the presence and 
absence of stimulation by Wnt ligand is depicted in Figure 3. In unstimulated cells, β-catenin 
is present in the cytoplasm together with the tumor suppressor adenomatous polyposis coli 
(APC), the constitutively active Glycogen synthase kinase 3β (GSK-3β), Casein kinase α-1 
(CSKA-1) and Axin (Kimelman & Xu 2006). In this complex, any free β-catenin is captured  
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and subjected to phosphorylation by GSK-3β at four N-terminal serine and threonine residues 
(Ikeda et al. 1998). The phosphorylation of β-catenin is recognized by different proteins like 
(Slimb/TrcP) and get conveyed to ubiquitin conjugating enzymes, which mark β-catenin for 
degradation (Jiang & Struhl 1998; Marikawa & Elinson 1998). The β-catenin is then rapidly 
degraded via the ubiquitin-proteasome pathway (Aberle et al. 1997). 
The proteins of the Wnt family stimulate the cells via binding of the Wnt ligands to the 
Fzd family of serpentine receptors (Bhanot et al. 1996). Wnt proteins comprise a large family 
of 19 identified family members till date, that have been found in round worms, insects, and 
vertebrates (Sidow 1992). Wnt proteins are secreted glycoproteins that have been shown to be 
associated with the cell surface receptors. (Mcmahon & Bradley 1990; Papkoff & Schryver 
1990). They are involved in a number of developmental and physiologic processes. The Low-
density lipoprotein receptor-related proteins (LRP) can bind together with Fzd to the Wnt 
proteins, thus activating the Wnt cascade (Pinson et al. 2000; Tamai et al. 2000). As a 
Figure 3: Schematic overview of the canonical Wnt signaling pathway. In the absence of 
wnt ligand β-catenin is phosphorylated in the destruction complex and tagged for 
ubiquitination. But in the presence of wnt ligand the destruction complex of β-catenin is 
inactivated and hence β-catenin is translocated in to the nucleus where it binds with LEF-
1 and plays a role of transcriptional co-activator expressing β-catenin/LEF-1 target 
genes. 
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consequence of this Wnt signal, GSK-3β is inhibited by the cytoplasmic protein Dishevelled 
(Dsh) (Noordermeer et al. 1994; Kishida et al. 1999; Smalley et al. 1999; Itoh et al. 2000), 
preventing the phosphorylation of β-catenin and its degradation. The cytoplasmic pool of free 
β-catenin, thus stabilized, translocates into the nucleus where it can interact with the nuclear 
mediators of Wnt signaling, the LEF/TCF proteins. This interaction leads to activation of the 
Wnt target genes by interaction with the mediators (Hsu et al. 1998). In the absence of a Wnt 
signal, LEF/TCF proteins cannot activate target genes. 
3.3.3. The LEF/TCF protein family 
 
The first members of the LEF/TCF family to be identified were T cell factor 1 (TCF-1) 
(Oosterwegel et al. 1991; Vandewetering et al. 1991) and Lymphoid enhancer factor 1 (LEF-
1) (Travis et al. 1991; Carlsson et al. 1993). Schematic representations of the structure of 
LEF-1 isoforms have been illustrated in figure 4. Proteins of the LEF/TCF family share an 80-
amino-acid high mobility group (HMG) box. It was shown that the HMG box can bind to 
DNA as a monomer in a sequence specific manner (Travis et al. 1991; Giese et al. 1991). 
Other features of LEF-1 are the β-catenin binding domain (βBD), through which the 
interaction with β-catenin is achieved, and the context dependent activation domain (CAD) 
that can interact for example with the Ally of AML-1 and LEF-1 (ALY), an ubiquitously 
expressed nuclear protein that was shown to be necessary for the T cell receptor α (TCRα) 
enhancer function (Bruhn et al. 1997) The LEF/TCF family members are expressed in a great 
variety of tissues such as immature T and B cells of adult mice and in the neural crest, 
mesencephalon, tooth germs, whisker follicles, and other sites during embryogenesis. It was 
shown that LEF-1 has an architectural function and can interact with different proteins that 
result in either activation or repression of target genes. For the activating effect, the LEF/TCF  
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family members mostly interact with β-catenin to turn on Wnt target genes what makes them 
a member of the Wnt signaling pathway for this regulation. In a distinct number of cases, 
LEF-1 can also positively regulate target genes without the help of β-catenin, thus acting 
independently of the Wnt pathway, as shown for example in the regulation of TCRα by LEF-1 
(Travis et al. 1991). 
On the other hand LEF/TCF proteins can also actively repress transcription. This was 
first observed with experiments in Drosophila and Xenopus, showing that in the absence of a 
Wnt/Wg signal the repression of Ultrabithorax (Ubx) and Siamois is released by mutating the 
LEF/TCF consensus sites in their transcriptional control elements (Brannon et al. 1997; Riese 
et al. 1997; Bienz 1998). There are some co-repressors known to directly interact with 
LEF/TCF proteins that help to repress target genes. Groucho is once such protein that binds to 
a part of the CAD domain of LEF-1, thereby allowing its binding to β-catenin at the same 
time leading to a repressive effect in the context of a Wnt signal. Repression of E-cadherin 
Figure 4: LEF-1 Isoforms (A) Schematic representation of LEF-1 splice variants and their 
most conserved domains. (B) Short forms of Lef-1 lack the N-terminal domain, which 
interacts with β-catenin. The CAD domain in Lef-1 is required for context-dependent 
activation of the TCR enhancer. The HMG box mediates sequence-specific DNA binding. 
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through LEF-1 and β-catenin interaction without the help of any co-repressors has also been 
shown (Jamora et al. 2003). Nevertheless it seems to be more likely, that the main mechanism 
for repression is mediated without the help of β-catenin. However the reports about the 
mechanism of repression through LEF-1 are contradictory and no main pathway was 
discovered yet. Thus, for the repressive effect of LEF/TCF proteins there are still a lot of 
questions to be answered. 
3.3.4. The Role of Wnt signaling in B-cell development 
 
LEF-1 is known to be expressed in transformed pre-B cell lines but rapidly down 
regulated in mature B cells (Travis et al. 1991). The other family members of the LEF/TCF 
family are not found to be expressed in any stage of the B cell development. Only little is 
known about the influence of Wnt signaling on B cell development. The first evidence that 
Wnt might play a critical role came from the finding, that some leukemic B cell lines 
overexpress a novel Wnt protein, Wnt 16 (McWhirter et al. 1999). The exact expression 
pattern of the Wnt proteins and LEF-1 in B cells and the role of Wnt signaling and LEF-1 in 
the development remained unclear. Recently the effects of LEF-1 on B cell development were 
subject to intensive analysis (Reya et al. 2000). First the precise pattern of LEF-1 in 
developing B cells was studied. It could be shown by lacZ reporter assay that LEF-1 is 
expressed during early B cell development in the fetal liver and adult bone marrow (Galceran 
et al. 2000). The upregulation occurs in fraction B pro-B cells and LEF-1 can also be detected 
in fraction C cells. There is no LEF-1 expression found in IgM-positive B cells from the adult 
spleen or adult bone marrow. To test for a correlation between the expression pattern and the 
function, fetal liver of Lef1-/- embryos and perinatal bone marrow was analyzed, as an 
analysis of older mice is not possible due to the early death of Lef1-/- mice. The number of 
B220+ cells was reduced by more than two fold and was even more obvious after excluding 
the dying and dead cells. To specify the stage of the cells, B220+ positive cells were tested for 
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other surface markers and it could be shown, that the majority of the B220+ cells were also 
CD43+, placing them in the pro-B cell compartment. To test if LEF-1 deficiency results in a 
differentiation defect, they tested bone marrow of mice at postnatal day 13 (P13) for the ratio 
of IgM- to IgM+ B lymphocytes. Although the total number of the cells was reduced as shown 
before, the ratio remained still the same and there were no defects in rearrangement of the 
immunoglobulin heavy and light chains occurring. These findings were also confirmed with 
adoptive transfer experiments where the mutant B cells behaved like wildtype cells in a 
wildtype environment. On further analysis the reduced number of B220+ cells was found to be 
due to reduced cell survival. With TUNNEL assay and Annexin V staining it could be shown 
that indeed the B220+ cells of Lef-1-/- mice die up to a 20-fold higher frequency. As a cause 
for the reduced survival, Reya and coworkers analyzed the expression level of several genes 
known to be involved in apoptosis. The levels of Bcl-2, Bcl-x, and p53 remained unchanged 
in sorted pro-B cells (fraction B) of Lef1-/- mice compared to wildtype, whereas the 
expression of Fas and c-myc was elevated. A second defect that can contribute to the reduced 
size of the B cell compartment is the diminished proliferation of the B cells. With a thymidine 
incorporation assay it could be shown, that in addition to the increased apoptosis, the 
decreased proliferation of B cells signifies that LEF-1 has an important function for the 
proliferation of B cells. As LEF-1 and β-catenin together are members of the Wnt signaling 
pathway, they went on testing the responsiveness of B cells to Wnt stimuli. While Wnt10B, 
Wnt3A, and Wnt5A were found to be expressed in bone marrow, only Wnt5A was expressed 
in the stromal cells of the bone marrow, indicating that the other family members are 
produced by the hematopoietic cells themselves. It could be shown that proliferation of 
wildtype pro-B cells is increased after LiCl stimulation and that the soluble Wnt3A could 
stabilize β-catenin in the cells. Furthermore comparing the responsiveness of wildtype and 
Lef1-/- cells to Wnt3A stimulation revealed the LEF-1 dependence. Only a small proportion of 
cells deficient for LEF-1 started to proliferate after Wnt3A addition whereas the majority of 
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the wildtype cells were found to start dividing. These findings taken together strongly indicate 
an essential role of Wnt signaling and LEF-1 expression for B cell development. Table 1 
shows the list of few validated target genes of TCF/LEF-1 based on the consensus binding 
sequence (5'-CCTTGAA-3’) in the promoter region of the gene. 
Table 1 List of target genes of Wnt/β-catenin/TCF/LEF-1 signaling 
Gene Organism/system References 
c-myc Human/colon cancer (He et al. 1998) 
n-myc Mesenchyme limbs (ten Berge et al. 2008) 
Cyclin D1 Human/colon cancer (Shtutman et al. 1999; Tetsu & 
McCormick 1999) 
LEF-1 Human/colon cancer (Hovanes et al. 2001; Filali et 
al. 2002) 
c-jun Human/colon cancer (Mann et al. 1999) 
Fra-1 Human/colon cancer (Mann et al. 1999) 
Axin-2 Human/colon cancer (Jho et al. 2002) 
CD44 Human/colon cancer (Wielenga et al. 1999) 
Dickkopf-1 Various cells/tumors (Chamorro et al. 2005; 
Gonzalex-Sancho et al. 2005) 
MMP-7 Human/colon cancer (Crawford et al. 1999; 
Gonzalex-Sancho et al. 2005) 
 
3.4. Wnt Signaling and Diseases 
 
The Wnt signaling being an important pathway in the development of B cells and in the 
delicate balance between apoptosis, survival and proliferation of B cells clearly implies that 
deregulation of this pathway would lead to manifestation of pathological conditions. Besides 
considerable advances in investigating the mechanisms of Wnt signaling and their role in 
development, recent studies implicate Wnt signaling in cancer and other clinical conditions 
(Moon et al. 2004; Polakis 2000; Giles et al. 2003; Lustig & Behrens 2003). 
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3.4.1. Role of Wnt signaling in human cancers and its therapy 
 
There have been numerous reports describing overexpression or under-expression of 
Wnt genes in cancer. A transgenic mouse model has established that tumor growth is 
dependent on Wnt-1 expression (Gunther et al. 2003). Studies of Wnt expression in human 
breast tumors have tended evidence to support Wnt signaling in development of breast cancer 
(Lane & Philip 1997; Huguet et al. 1994; Smalley & Dale 2001; Howe & Brown 2004). Cells 
expressing Wnt1 were resistant to cancer therapy mediated apoptosis. Wnt1 signaling 
inhibited cytochrome c release and the subsequent caspase-9 activation that was induced by 
chemotherapeutic drugs, including both vincristine and vinblastine. Further research showed 
that Wnt1 signaling inhibited apoptosis by activating β-catenin/Tcf mediated transcription 
(Chen et al. 2001). It was recently demonstrated that inhibition of Wnt2 mediated signaling 
induced apoptosis in both malignant melanoma cells and non-small-cell lung cancer cells 
(You et al. 2005; You et al. 2004). These studies show that activation of the β-
catenin/TCF/LEF-1 signaling pathway by Wnt ligands not only provides a growth advantage 
to cancer cells, but also significantly affects the clinical outcome by inhibiting chemotherapy-
induced apoptosis. Blocking Wnt signaling, for instance with a monoclonal antibody or 
development of small molecules can be useful to inhibit the Wnt/β-catenin signaling pathway 
for treatment of cancer patients and may improve the efficacy of chemotherapy by enhancing 
apoptosis in cancer cells. 
3.4.2. Role of Wnt signaling in B Chronic lymphocytic leukemia (B-CLL) 
 
As previously mentioned Wnt signaling is active during early B cell development in a 
LEF-1 dependent mechanism (Reya et al. 2000). However some studies exist that indicate 
factors governing aberrant activation of Wnt signaling in mature B-CLL cells. A 
comprehensive gene expression profiling from two independent studies revealed that LEF-1 
mRNA was  ~3000 fold overexpressed in B-CLL when compared to its healthy counterpart 
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(Gutierrez et al. 2007; Howe & Bromidge 2006). Later series of studies demonstrated 
autocrine activation of Wnt signaling in different clinical subsets of CLL. Based on a cDNA 
microarray study, Wnt-3 was found to be uniformly upregulated in B-CLL (Rosenwald et al. 
2001). Lu and co workers demonstrated that B-CLL cells are in an autocrine Wnt action 
where several Wnts and frizzled (Wnt-3, Wnt-5b, Wnt-6, Wnt-14, Wnt-16, Fzd-3) mRNA 
were found to be elevated in CLL when compared to healthy B cells. The induction of β-
catenin by inhibiting GSK3-β also demonstrated an increased survival of B-CLL cells in vitro, 
whereas inhibiting Wnt signaling by R-etodolac led to apoptosis in CLL cells indicating that 
this pathway plays a crucial role in survival of CLL cells. (Lu et al. 2004).  
There are also evidences for epigenetic alterations of modulators of Wnt signaling at 
the genomic level. Secreted frizzled-related proteins (SFRP-1, SFRP-2 SFRP-4 and SFRP-5) 
was found to be frequently methylated in CLL (Liu et al. 2006; Chim et al. 2008). SFRPs are 
physiological inhibitors of Wnt pathway, which compete with the Fzd receptors for Wnt 
binding through the CRD domain or by binding directly to Fzd, resulting in the formation of 
inactive complexes with the receptor. The Wnt inhibitory factor-1 (Wif-1) which can bind to 
different Wnts and render them inactive is infrequently methylated in CLL (Chim et al. 2006).  
Taken together, there is an autocrine Wnt secretion in CLL cells, with overexpression 
of LEF-1 and concordant methylation of physiological inhibitors of Wnt pathway. As a result 
of such activation, LEF-1 target genes such as c-myc cyclin D1 are overexpressed in CLL 
cells providing extended survival of CLL cells (Faderl et al. 2002; Nagy et al. 2003; Plate et 
al. 2000). 
3.5. Clinical perspective of B-Chronic lymphocytic leukemia (B-CLL) 
Given the potential therapeutic value of the Wnt signaling pathway in the treatment of 
B-CLL, it is critical to understand the clinical perspective of the disease with regard to the 
epidemiology, symptoms, diagnosis, disease staging, and prognosis in order to develop the 
most effective therapeutic strategies. 
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3.5.1. Epidemiology 
 
CLL is the most common type of leukemia in the western countries representing 22- 
30% of all leukemia’s with an incidence rate of between 1 and 5.5 per 100,000 people and is 
considered incurable with currently available therapy (Redaelli et al. 2004; Zent et al. 2001). 
Geographically it is most prevalent in Australia, USA, Italy, Switzerland and Ireland, while 
low incidence is seen among Asian countries and US asian origin and is slightly more 
common in whites than in blacks, which emphasizes the racial factors in the occurrence of 
this disease (Dores et al. 2007; Groves et al. 1995; Morton et al. 2006). It mostly affects the 
elderly (>50yrs of age) however an increase in the incidence among the younger individuals 
has been reported (de Lima et al. 1998; Derossi et al. 1989; Mauro et al. 1999). CLL is more 
common in men than women with a sex ratio of about 2:1 (Cartwright et al. 2002). 
3.5.2. Clinical manifestations 
CLL is initially asymptomatic and often diagnosed during routine examination. Despite 
its lack of visible manifestation in terms of symptoms it affects the immune system leading to 
the complications like infections and secondary malignancies (Anaissie et al. 1998). Apart 
from infection patients can present features like painless lymphoadenopathy (enlargement of 
lymph nodes), bone marrow infiltration with leukemia cells causing anemia (low RBC levels) 
and thrombocytopenia (low platelets levels) (Mauro et al. 1999). Autoimmune hematological 
conditions are frequently associated with CLL, of which autoimmune haemolytic anemia 
(AHA), idiopathic thrombocytopenic purpura and red cell aplasia are more common (Diehl & 
Ketchum 1998; Mauro et al. 2000). Hypogammaglobulinemia (low gamma globulin levels) is 
found in approximately 50% of CLL patients (Dighiero G. 1988). 
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3.5.3. Diagnostic criteria 
 
The current diagnosis of CLL is based on the revised guidelines from the national 
cancer institute working group (NCI-WG) (Cheson et al. 1996; Hallek et al. 2008). 
Accordingly CLL can be diagnosed when the following conditions exist: 
1) A persistent (>3 month) peripheral blood lymphocyte count > 5 x 109 cells/L of mature 
lymphocytes in the absence of other causes 
2) Distinct immunophenotype of CLL  
a) Predominant expression of B cell markets like CD19, CD20, CD23 along with T 
cell marker CD5 antigen, in the absence of other T cell markers 
b) Light chain restriction and FMC7 negative 
c) Surface immunoglobulin (sIg) of low density and absence or low expression of 
CD79b 
Several hematological disorders like mantel cell lymphoma (MCL), splenic marginal 
zone lymphoma (SMZL), B cell prolymphocytic leukemia (PLL), Hairy cell leukemia (HCL) 
and Waldenstrom’s macroglobulinemia resemble CLL in their clinical presentation and 
microscopic appearance (Jaffe 2001). Therefore a differential diagnosis is necessary to 
distinguish CLL from other disorders. MCL differs from CLL by CD23 negativity and 
presence of t (11; 14) translocation (Sanchez et al. 2002). In addition, PLL and HCL are 
morphologically and immunophentoypically distinct from CLL. Clinically PLL and HCL 
have prominent splenomegaly without lymphoadenopathy. The immunophenotypic features 
of PLL and HCL differ from CLL, since they are negative to CD5 and CD23, while positive 
for FMC7 (Melo 1986; Sanchez et al. 2002). SMZL cells are morphologically distinct from 
CLL lymphocytes, with a plasmacytoid basophilic cytoplasm (Catovsky & Matutes 1999). 
Waldenstrom’s macroglobulinemia is distinct from CLL, with exception of hyper viscosity 
syndrome associated with  as a result of elevated immunoglobulin M (Chng et al. 2006). 
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3.5.4. Disease staging 
 
Clinical staging is important in CLL to predict prognosis, which aids in comparison of 
clinical findings and establishment of therapeutic guidelines. The Rai and Binet staging 
systems (Table 2 ) are two traditional clinical staging systems which are currently in practice 
(Binet et al. 2006; Rai et al. 1975).  
Table 2: Staging Systems for Chronic Lymphocytic Leukemia 
Stage Clinical features Median 
survival (y) 
Rai staging system   
Original Modified   
0 Low Lymphocytosis only >10 
I Intermediate Lymphocytosis and lymphoadenopathy 9 
II  Lymphocytosis and splenomegaly with or 
without  lymphoadenopathy 
7 
III High Lymphocytosis and anemia (H<11g/dL) 5 
IV  Lymphocytosis and lymphoadenopathy 
(platelets <100 x 109/L) 
     5 
 
 
 
 
 
Binet staging system 
  
A Lymphocytosis and lymphoadenopathy in 
<2 LN regions, Hb≥10g/dL and platelets 
≥100 x 109/L 
>7-10 
B Lymphoadenopathy at >3 sites in the 
absence of anemia or thrombocytopenia, 
Hb≥10g/dL and platelets≥ 100 x109/L 
5-7 
C Anemia (Hgb<10g/dL) and /or 
thrombocytopenia (platelets <100x106/dL) 
with or without lymphoadenopathy 
<2-5 
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3.5.5. Prognostic factors 
With the development of technology and growing insight into the biology of the 
disease, new prognostic markers became available such as cytogenetics, the mutational status 
of the immunoglobulin heavy chain variable genes (IgVH), zeta associated protein kinase 70 
kDa (ZAP-70) and CD38. These new prognostic markers allow stratifying patients into risk 
categories at the moment of the initial diagnosis. However further prospective trials are 
necessary to verify and establish their usefulness in the management of the patients with CLL 
(Binet et al. 1981). 
3.5.5.1. Cytogenetic abnormalities 
 
There is no single characteristic cytogenetic abnormality in CLL (Montserrat & 
Rozman 1995). With the development of interphase fluorescence in situ hybridization (FISH) 
techniques, it has become possible to detect numerical and structural chromosomal 
abnormalities in non dividing cells. Using FISH probes cytogenetic lesions were found in 
more than 80% of examined CLL cases, which is more than those detected in conventional 
metaphase cytogenetics and indicates prognostic applicability (Dohner et al. 2000; Krober et 
al. 2002). The most common cytogenetic alterations include deletion of 13q14.1, deletion of 
11q22.3-23.1, trisomy 12 and deletion of 17p13 (Anastasi & Le Beau 1992; Stilgenbauer et 
al. 1998). Table 3 shows the correlation of specific chromosome aberration with clinical 
characteristics and outcome in CLL patients (Montillo et al. 2005). A recent study analysed 
survival of CLL patients in relation to chromosomal abnormalities using FISH. There is 
increasing evidence that chromosomal abnormalities were associated with prognosis in 
retrospective and prospective clinical trials (Catovsky 1989; Shanafelt et al. 2006). In a 
prospective study 13q deletion was correlated with a favourable prognosis and 17p deletion is 
associated with most unfavourable prognosis among the occurring abnormalities (Grever et 
al. 2007; Shanafelt et al. 2006). Chromosome 17 abnormalities have been associated with p53 
mutation and with poor response rates and resistant to standard chemotherapeutic regiments 
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employing alkylating drugs and purine analogues (Byrd et al. 2006). For all these reasons 
during clinical trials, it is recommended to perform cytogenetics prior to treating a patient 
(Hallek et al. 2008). 
 
 
Table 3: Cytogenetics in CLL (Modified from Montillo et al., 2005) 
Chromosomal 
Aberrations 
Clinical Outcome Frequency 
% 
Median 
Survival 
(months) 
13q Favourable outcome if isolated aberration 55 133 
Trisomy 12 Atypical morphology and intermediate 
outcome 
16 114 
11q Extensive lymphoadenopathy, shorter 
treatment and free survival 
7 32 
17p Resistance to chemotherapy 7 32 
Normal karyotype Favourable outcome 18 ≥ 133 
 
 
3.5.5.2. IgVH mutational status 
 
During recent years, the somatic hypermutation status of the immunoglobulin variable 
heavy chain (IgVH) genes has been vividly investigated and found to be an important 
prognostic marker in CLL (Damle et al. 1999; Hamblin et al. 1999). A rearranged clonal 
IgVH sequences that differ from their germline counter parts by 2% are defined as ‘mutated’ 
(Dighiero G. 1988; Hashimoto et al. 1995; Schroeder & Dighiero 1994). Based on this 
subjective threshold value, two subgroups of CLL with clear difference in survival have been 
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identified as ‘mutated’ CLL, where leukemic cells have rearranged VH genes with 2% or 
more mutations and ‘unmutated’ CLL with few or no mutations (Fais et al. 1998; Stevenson 
& Caligaris-Cappio 2004). Mutational status has been strongly correlated with prognosis of 
CLL. Patients with unmutated gene sequences had aggressive disease, shorter survival and 
poorer prognosis than those with mutated genes (Krober et al. 2002; Oscier et al. 2002). Also 
there are reports indicating that patients with unmutated IgVH genes had a higher risk of 
relapse after stem cell transplantation (Ritgen et al. 2003). However, there is an exception, 
where the usage of IgVH gene V3-21 expression has an inferior outcome independent of the 
mutational status (Thorselius et al. 2006; Tobin et al. 2002). 
3.5.5.3. Zeta-associated protein (ZAP-70) 
 
Zeta-associated protein (ZAP-70) is an intracellular tyrosine kinase that is 
predominantly expressed in T and natural killer cells and functions in transmitting activation 
signals involved in T-cell receptor signaling and T cell activation (Chan et al. 1992). 
Microarray studies reveal that CLL cells share a characteristic gene-expression profile and 
found that a small number of genes (ZAP-70 and C-type lectin) correlated with the mutational 
status of IgVH genes (Klein et al. 2001; Rosenwald et al. 2001). Several studies using 
western blotting, RT-PCR and flow cytometry have confirmed the ability to distinguish 
between IgVH mutated (ZAP-70- ) and unmutated (ZAP-70+) (Crespo et al. 2003; Orchard et 
al. 2004; Rassenti et al. 2004). Many groups have validated a threshold of 20% by flow 
cytometry to separate ZAP-70- from ZAP-70+ cases (Crespo et al. 2003). As IgVH 
sequencing is laborious and costly, ZAP-70 expression is  recommended as surrogate marker 
for IgVH gene mutational status in CLL (Del Principe et al. 2006; Wiestner et al. 2003).  
3.5.5.4. CD38 expression 
 
CD38 is a cell surface molecule that regulates cell activation, proliferation and 
adhesion and present in various lineages of hematopoietic cells, including B-cells (Cruse et al. 
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2007). Recently it has been shown to promote proliferation and to prolong survival of CLL 
cells (Deaglio et al. 2006). CD38 was initially suggested as a surrogate marker for IgVH 
mutation status in CLL (Damle et al. 1999; Ibrahim et al. 2001). High CD38 expression 
correlates with unmutated IgVH and is associated with significantly shorter overall survival, 
progression-free survival times and poor response to chemotherapy (Del Poeta et al. 2001; 
Ghia et al. 2003; Jelinek et al. 2001). However other studies found CD38 expression gives 
discordant results with respect to IgVH mutation status (Hamblin et al. 2000; Krober et al. 
2002). This discrepancy is due to the lack of a defined cut-off value for CD38 expression 
(Boonstra et al. 2006; Krober et al. 2002) and also change in the expression of CD38 with 
time, especially after initiation of therapy (Hamblin et al. 2002). 
3.6. Current Therapeutic strategies 
Remarkable progress in elucidating the biology of CLL has been made over the last 
two decades. Improved understanding of CLL has lead to new prognostic tools and 
therapeutic options, and holds promise for eventually finding a cure for this disease. 
Challenges lie in incorporating the various treatment modalities, including chemotherapy, 
monoclonal antibodies, immunotherapeutic strategies and novel small molecules, into a 
comprehensive treatment strategy guided by the biological complexity of CLL. 
3.6.1. Criteria for patient treatment 
The disease course for CLL is highly variable and the criterion for initiating the therapy 
is an important consideration in the clinical management of CLL. The decision to treat is 
guided by the stage of the disease, the presence of symptoms and disease progression 
(Eichhorst & Hallek 2007). According to the guidelines for diagnosis and treatment (Hallek et 
al. 2008) set at the recent International Workshop on Chronic Lymphocytic Leukemia 
(IWCLL) indicate that in routine clinical practice, newly diagnosed patients with 
asymptomatic early stage disease should be kept under ‘wait and watch’ unless there is 
evidence of disease progression. Several research groups confirm that the treatment of early-
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stage disease with alkylating agents does not prolong the survival (Dighiero et al. 1998). 
However symptomatic and progressive disease patients (Rai III and IV or Binet B or C) 
should be immediately treated to benefit initiation of treatment (Molica et al. 1991; Robak et 
al. 2006a). Improvement in therapeutic regiments and advances in the understanding the 
biology of the disease have made it possible to achieve higher percentage of remissions, but 
never a complete remission of the disease. A complete cure of this disease is still a far-to-
reach goal of modern medicine (Ghia et al. 2007). 
3.6.2. Alkylating agents as single agents and in combination therapy 
 
For many years alkylating agents like chlorambucil have been the gold standard for the 
first line therapy in CLL, given daily or intermittently, alone or in association with 
corticosteroids. Chlorambucil produced overall remission rate of 40-80% in previously 
untreated patients and all the patients showed a relapse (Binet 1990; Rai et al. 2000; Keller et 
al. 1986). Despite higher response rates chlorambucil does not prolong survival and use of 
corticosteroids does not provide any benefit in the treatment (Catovsky et al. 1991; Dighiero 
et al. 1998; Jaksic et al. 1997). Another alkylating agent, cyclophosphamide is used when 
chlorambucil is poorly tolerated. A higher response rate was achieved when this drug used in 
combination therapies with anthracyclines. The best combination therapies were CHOP 
(cyclophosphamide, adriamycin, vincristine and prednisone), CAP (cyclophosphamide, 
doxorubicin and prednisone) and COP (cyclophosphamide, vincristine and prednisone) 
(Keating et al. 1988; Jaksic et al. 1997; Binet 1990). In most randomized studies and meta 
analyses of randomized trials of these combination chemotherapy regiments showed a higher 
response rates, but none showed a benefit in terms of survival (Binet 1990; Raphael et al. 
1991). 
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3.6.3. Purine analogs as single agents and in combination therapy 
 
Purine analogs have become the gold standard for first line treatment in CLL replacing 
monotherapy with alkylating agents (Keating et al. 1991). Three purine analogues are 
currently used in CLL: fludarabine, pentostatin and cladribine. Fludarabine is most 
extensively studied and used for therapy in the west and in Europe. Fludarabine monotherapy 
induces more complete remissions when compared with other treatment regiments containing 
alkylating agents or corticosteroids (Keating et al. 1991; Rai et al. 2000; Johnson et al. 1996; 
Keating et al. 1998; Leporrier et al. 2001). Single agent fludarabine has superior response 
rates in previously treated patients (Hallek et al. 2001) and also in elderly patients with 
progressive disease (Eichhorst & Hallek 2007). Randomized studies of cladribine show 
similar overall and complete remission as with fludarabine as single agent or in combination 
in CLL (Robak 2002; Montillo et al. 2003). 
3.6.4. Chemoimmunotherapy 
 
Monoclonal antibodies and immunotoxins are emerging as attractive agents and have 
been investigated in clinical trials in patients with CLL (Del Poeta et al. 2008; Robak et al. 
2006b; Tam & Keating 2007). Rituximab (Rituxan, Mabthera) is a chimeric human mouse 
monoclonal antibody that targets CD20 antigen. CD20 antigen is expressed in all B-cell 
phases except stem cells and plasma cells. Rituximab’s anti-leukemia action includes 
elimination of B cells includes complement dependent lysis, antibody dependent cell 
mediated cytotoxicity (ADCC) and direct induction of apoptosis (Voso et al. 2002). Single 
agent rituximab has limited efficacy at standard FDA approved doses and most studies 
suggested a higher dose of rituximab in CLL when compared to other lymphomas (Voso et al. 
2002; Byrd et al. 2001; Itala et al. 2002; O'Brien et al. 2001). The combination of rituximab 
with fludarabine (Byrd et al. 2003; Schulz et al. 2002) or fludarabine and cyclophosphamide 
(Keating et al. 2004) increased the overall and complete remission rates in previously 
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untreated patients and in the relapsed CLL patients (Wierda et al. 2005). Alemtuzumab 
(Campath) is a recombinant, fully humanized, monoclonal antibody against CD52 antigen. 
Several reports have confirmed significant overall response rate and survival activity 
alemtuzumab in relapsed or refractory CLL (Keating et al. 2002; Osterborg et al. 2002; Rai et 
al. 2002). In addition, alemtuzumab showed clinical response in patients with poor prognostic 
factors, including high-risk genetic markers such as deletions of chromosome 11 or 17 and 
p53 mutations (Lozanski et al. 2004; Stilgenbauer et al. 2001).  
3.6.5. Allogeneic transplant 
A recent consensus paper by EMBT (European Group for Bone Marrow 
Transplantation) provided standard indications for allogeneic transplant in CLL. The authors 
contend that allogeneic HCT (Hematopoietic cell transplantation) has proven efficacy in poor-
risk CLL, for younger patients with 1) non response or early relapse with 12 months after 
purine analog treatment. 2) Relapse within 24 months after achieving CR (Complete 
Remission) with a purine analog based regimen. Or 3) patients with 17p- abnormalities with 
dismal responses with conventional chemotherapy regimens (Dreger et al. 2007). Several 
nonrandomized trials have evaluated the efficacy of allogeneic stem cell transplantation in 
CLL. However, most trials were limited by size, absence of long term follow up and high 
treatment related mortality (Jabbour et al. 2004). A recent Spanish study reported 30 patients 
with poor-prognosis CLL and or high-risk molecular/cytogenetic characteristics, treated with 
reduced intensity conditioning (RIC) allogeneic transplant indicate that this therapy may 
overcome adverse prognostic factors even in patients with 17p-, and provide patients with 
long term remission suggesting potential cure. 
3.6.7. Other Targeted therapies 
 
Apart from immunotherapy, few targeted therapies are being tested in clinical trials for 
CLL. Oblimersen, an antisense phosphothioate oligonucleotide targets the messenger RNA of 
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the anti-apoptotic molecule BCL-2. As a single agent oblimersen confirmed only modest 
activity in patients with relapsed/refractory CLL (O'Brien et al. 2005) but demonstrated 
favourable activity in combination with FC (Fludarabine-Cytoxan), compared to FC alone 
(O'Brien et al. 2007). ABT-263 is a BH3 mimetic that binds and inhibits multiple anti-
apoptotic BCL-2 family proteins and potent against cell lines derived from lymphoid and 
small cell lung cancers as single agent. Currently combination strategies using ABOUT-263 
with rituximab or chemotherapy are underway or in planning phase (O'Connor et al. 2008). 
As CLL is still an incurable disease with high relapse rates with current treatment 
regimens, there is still a great need to investigate novel drugs and to understand in detail the 
underlying molecular mechanism in the pathogenesis of the disease 
3.6.8. Novel TCF/LEF-1/β-catenin Inhibitors CGP049090 and PKF115-584 
 
The interaction between TCF family transcription factors and β-catenin requires a 
minimal N-terminal C fragment and central domain of 12 armadillo repeats in β-catenin. A 
recent high throughput screening explored the compound libraries in search of small 
molecules which inhibit the TCF/LEF-1/β-catenin interaction. Out of approximately 7,000 
natural compounds, very few displayed reproducible and dose-dependent inhibition of the 
protein-protein interaction between β-catenin and Tcf4 in an immunoenzymatic assay with 
IC50 values lower than 10µM. Six compounds were evaluated in a range of in vitro secondary 
assays such as reporter gene activation, expression analysis, cell proliferation, and xenopus 
duplication assay. Three compounds (PKF115- 584, CGP049090, and PKF222-815), with the 
same chemical core structure, scored consistently in the different assays (reporter gene assays, 
GST-pulldown assay, electrophoretic mobility shift assay) used to confirm the antagonistic 
properties of the compounds. We obtained two of these compounds CGP409090 and 
PKF115-584 (Synonym: Calphostin C) from Novartis Pharma AG (Basel) (Figure 5). Both 
CGP049090 and PKF115-584 are extracts from fungal organisms and are aromatic 
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heterocyclic compounds. Due to their heterocyclic nature they possess auto-fluorescence 
properties. The Molecular weight of PKF115-584 is 790.70g/mol and CGP049090 is 
534.52g/mol. Figure 5 also depicts the molecular mechanism of the action of these 
compounds in the disruption of the Wnt signaling pathway 
 
Figure 5: Molecular structure of PKF115-584 and CGP049090 and the potential 
mechanism of the disruption of Wnt signaling pathway 
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3.7. Project Objectives 
B-Cell Chronic lymphocytic leukemia (B-CLL) is the result of progressive 
accumulation of dysfunctional monoclonal B lymphocytes. Several aberrant pathways have 
been implicated in this disease leading to its extended survival. Current treatment options 
include the use of traditional chemotherapy with or without in combination of antibody 
therapy and allogeneic transplantation. Despite availability of current treatment options, B-
CLL still remains an incurable disease. 
Over the last few years there has been considerable focus on role of Wnt signaling and 
malignant diseases. Classically Wnt signaling is active in early developmental tissues and is 
turned off in adult differentiated tissues. However, positive Wnt signaling has been fairly 
established in most of the cancer types. Little is known about the Wnt signaling in B-CLL. A 
micro-array study revealed that an important transcription factor of Wnt signaling pathway 
LEF-1, is 3000 fold over-expressed in CLL cells when compared to healthy B cells. 
Therefore, the central aim of this thesis is to determine whether LEF-1 is an attractive 
therapeutic target for B-CLL therapy. 
This would be systematically accomplished by  
 Confirming the expression of Wnt signaling components in B-CLL cells, cell lines and 
healthy cells at the protein level 
 Investigating the role of LEF-1 in extended survival of B-CLL cells and cell lines by 
siRNA knockdown 
 To test novel small molecule inhibitors (CGP049090 & PKF115-584) of the LEF-1/ β-
catenin complex in B-CLL in vitro and in a suitable mouse model in vivo. 
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4. Results 
The current study was undertaken to investigate if LEF-1 could be a potential 
therapeutic target for B-CLL. In order to study this, the activation of Wnt signaling pathway 
was first characterized in the various cell lines used and the need for LEF-1 for the survival of 
B-CLL was ascertained. Following this, the two small molecule inhibitors, CGP049090 & 
PKF115-584 were tested and analysed for inhibition of LEF-1/ β-catenin interaction in the in 
vitro and in vivo context. 
4.1. Activation of Wnt signaling in B-CLL 
The extracellular Wnt signal is transduced by transmembrane and cytoplasmic 
mediators which ultimately lead to dephosphorylation of β-catenin. β-catenin can then 
translocate into the nucleus where it can interact with LEF-1 and initiate target gene 
expression (Morin & Weeraratna 2003). This LEF-1/ β-catenin complex is considered to be a 
trademark canonical Wnt pathway. Hence, monitoring the increase of dephosphorylated β-
catenin and LEF-1 served as a surrogate marker for activation of Wnt pathway. 
4.1.1. Expression of downstream signaling components of Wnt signaling in 
B-CLL and healthy B cells. 
 
The levels of LEF-1/ dephospho β-catenin were compared in primary CLL samples and 
CLL cell lines to that of the healthy B cells and PBMCs. Briefly   total protein extracts were 
made from primary B-CLL cells (n=7) healthy B cells (n=2) healthy PBMCs (n=2) and JVM-
3 and MEC-1 cell lines. 10µg of the cell lysate were subjected to western blot analysis to 
detect LEF-1, total β-catenin, dephospho β-catenin (active beta catenin). Equal protein 
loading was assured by measuring ubiquitously expressed β-actin (Figure 5). There was a 
significant over-expression of LEF-1 in B-CLL samples when compared to the healthy B cells 
and PBMCs. LEF-1 expression is completely turned off in healthy B cells. The total β-catenin 
and dephospho β-catenin pool was also higher in B-CLL samples when compared to healthy  
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B cells and PBMCs. The presence of LEF-1 and dephospho β-catenin in B-CLL confirms the 
LEF-1/ dephospho β-catenin complex formation thereby the potency to transcribe target 
genes. 
4.1.2. Nuclear localization of LEF-1 and β-catenin in primary B-cells 
 
LEF-1 which exists as a repressor in the nucleus is transformed to a transcriptional co-
activator by complexing with dephospho β-catenin in the nucleus upon stimulation with Wnt 
ligands. Hence the presence of this complex in the nucleus regarded as the functional 
significance of this pathway as it can direct transcription of various LEF-1 target genes. To 
demonstrate that the leukemic B-CLL cells have an aberrant and constitutive activation of 
Wnt signaling nuclear and cytoplasmic extracts from three B-CLL patient samples were made 
and probed for the localization of LEF-1, total β-catenin and β-actin as loading/purity control 
(Figure 7). It was evident that LEF-1 is primarily localized in the nucleus along with β-catenin 
indicating both proteins interact and can transcribe LEF-1 target genes in B-CLL. However 
residual amount LEF-1and β-catenin was also seen in the cytoplasmic extract. Interestingly  
Figure 6: LEF-1 and β-catenin expression in CLL, cell lines and healthy B cells. Total 
protein extracts from primary B-CLL (n=7), healthy CD 19+ B cells (n=2), healthy 
PBMCs (n=2), and B-CLL cell lines were probed for LEF-1, total β-catenin, and 
dephospho β-catenin and β-actin as loading control. 
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the B-CLL cells also express a short isoform (~45kDa) and a longer isoform (~56kDa) of 
LEF-1. The antibody against LEF-1 used in this study only detects the dominant from of LEF-
1 which has the β-catenin binding domain. Hence both isoforms of LEF-1 can interact with β-
catenin and then act as a transcriptional co-activator in the nucleus. As seen from the figure 7 
the longer isoform of LEF-1(56kDa) is predominantly localized in the nucleus whereas the 
shorter isoform (45kDa) is located in both cytoplasm and the nucleus. 
4.2. LEF-1 plays a central role in for survival of B-CLL cells 
Following characterisation of the Wnt signaling pathway in the various cell lines, it was 
ascertained that LEF-1 is indeed required for the survival of B-CLL before investigating Lef-1 
as a target for inducing apoptosis of B-CLL. 
4.2.1. Knockdown of LEF-1 in primary CLL cells by siRNA 
Having established that the Wnt signaling is constitutively activated in B-CLL, it was 
essential to determine the role of LEF-1/β-catenin transcription in the survival of B-CLL cells. 
Most of the LEF-1 targets are known oncogenes and play a vital role in tumorigenesis. 
Figure 7: Nuclear localization of LEF-1 and β-catenin in primary B-CLL cells. Nuclear 
and cytoplasmic extracts from 3 primary B-CLL samples indicate both LEF-1 isoforms 
are predominantly localized in the nucleus along with β-catenin. β–actin served as the 
loading control and to determine purity of the nuclear extract. 
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SiRNA mediated LEF-1 knockdown experiments was carried out in primary B-CLL 
cells by nucleofection. LEF-1 knock down was determined at the protein level in three 
representative samples by immunoblotting using anti LEF-1 antibody and anti β-actin 
antibody as loading control (Figure 8A). Figure 8B indicates the % inhibition of in LEF-1 in 
the sample transfected with LEF-1 siRNAs when compared to nontargeting control siRNA by 
densitometry analysis using β-actin as the reference band. This validates that LEF-1 
knockdown promotes apoptosis of B-CLL cells. 
A 
                    B 
 
 
 
Figure 8: (A) Knockdown of LEF-1 in primary CLL cells by siRNA 
LEF-1 expression was analyzed by western blot in total cell extracts from of indicated 
patient samples with anti-β-actin as the loading control.(B)Densitometry analysis of % 
Inhibition of Lef-1 
For each of the 3 samples, blot lanes corresponding to control nontargeting and LEF-1 
siRNA were subjected to densitometric analysis and normalized to β-actin levels. Columns 
represent the percentage inhibition of LEF-1 induced by LEF-1 siRNA compared to 
control siRNA. 
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4.2.2. siRNA mediated LEF-1 knockdown induces apoptosis in primary CLL 
cells 
 
The cell viability following the siRNA knockdown of Lef-1 was determined 16 hours 
post nucleofection by flow cytometry by annexinV/PI staining. The cells nucleofected with 
LEF-1 siRNAs had a significantly increased rate of apoptosis when compared to the cells 
nucleofected with nontargeting siRNAs. The percent survival (mean ± s.e of six samples) was 
45.02% ± 3.7 in the control siRNA transfected cells and 32.46% ± 3.6 in the LEF-1 
transfected cells (p value= 0.031) as shown in the Figure 9. 
 
 
 
 
 
 
Figure 9: siRNA mediated LEF-1 knockdown induces apoptosis in primary CLL cells. 
Freshly isolated B-CLL cells were non transfected (NT), mock transfected (no siRNA), 
transfected with 0.5µM control non targeting or LEF-1 siRNA (n=6) and cultured for 16h 
in complete medium. (A) Cell viability was evaluated by annexin-V/PI staining and the 
results from each patient are presented as the percentage of annexin-V-/PI- cells (%viable 
cells). (B) The same result represented as M±SE indicates the significant difference 
between the control siRNA Vs LEF-1 siRNA ( p value =0.031) 
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4.2.3. Knockdown of LEF-1 in JVM-3 cell lines by siRNA leads to down 
regulation of target genes and reduced proliferation 
 
Till date, JVM-3 and MEC-1 is among the few cell lines that can be considered CLL 
like cells. They were originally derived from a patient with B-prolymphocytic leukemia (PLL) 
at diagnosis and EBV-transformed during treatment with phorbol ester TPA. JVM-3 cell lines 
express κ light chains, surface CD19, and CD23. To evaluate the effects of LEF-1 knock 
down in JVM-3 cell lines siRNA mediated LEF-1 knock down experiments were carried out. 
 
 
 
Figure 10: Knockdown of LEF-1 in JVM-3 cell line by siRNA leads to reduced 
proliferation. 
LEF-1 knock down experiments in JVM-3 cell lines shows down regulation of target gene 
expression of c-myc, cyclin D1, PARP and PCNA when compared to the control. Levels of 
β-catenin remained unchanged. This observation was confirmed in two independent 
experiments. 
Results 
 
41 
48 hours post siRNA nucleofection cells were harvested and protein extracts were 
immunoblotted for lef-1, β-catenin, c-myc, cyclin D1, PCNA, cleaved PARP and β-actin as 
the loading control. Figure 10 shows that LEF-1 knock down, leads to expected inhibition of 
LEF-1 target genes like c-myc and cyclin D1. Surprisingly, LEF-1 knockdown lead to 
decreased rate of proliferation rather than apoptosis, as seen by decreased expression of 
PCNA. PCNA is expressed in the nuclei of cells during the DNA synthesis phase of the cell 
cycle and hence considered as a marker for proliferation (Leonardi et al. 1992). Significant 
inhibition of PARP was also seen but cleaved PARP was not detectable indicating lack of 
apoptotic induction. However, the levels of β-catenin remained stable; indicating β-catenin 
expression is independent of LEF-1 expression in B-CLL. 
4.3. In vitro cytotoxicity of small molecules (CGP049090 and PKF115-584) 
The cytotoxic potential of the small molecule inhibitors, CGP049090 and PKF115-584 
by the disruption of β- catenin/LEF-1 signaling in CLL was ascertained in vitro in B-CLL and 
healthy cells. 
4.3.1. Cell lines 
 
MEC-1 and JVM-3 cell lines were treated with different concentrations of CGP049090 
and PKF115-584 (10, 1, 0.1, 0.01 µM) along with the DMSO vehicle control for 24h. The cell 
viability was determined using an ATP dependent cell viability assay Dose response curves 
and LC50 were calculated using GraphPad Prism™.  Figure 10 shows both small molecule 
inhibitors inhibited the survival of these cells in a dose-dependent manner. The LC50 value 
was found to be 0.12 µM for CGP049090 and 0.49 µM for PKF115-584 in MEC-1 cells 
(Figure 11B) and 0.42 µM for CGP049090 and 0.93 µM for PKF115-584 in JVM-3 cells 
(Figure 11A). 
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4.3.2. Healthy B cells and Primary CLL cells 
 
As B-CLL is a highly complex and heterogeneous disease we performed ATP 
dependent cell survival assays in 20 different B-CLL samples, in order to illustrate the distinct 
in vitro cytotoxic response that these compounds have with respect to different subsets of 
CLL. CLL cells from patients and purified healthy B cells from healthy volunteers were 
similarly treated as the cell lines. Figure 12 shows the dose response curves in 24 B-CLL 
patients and 3 healthy B cell volunteers. Interestingly The LC50 value was found to be e 
0.89µM for CGP049090 and 0.77 µM for PKF115-584 in primary CLL cells and 8.5µM for 
CGP049090 and 5.7µM for PKF115-584 in healthy B cells. Both small molecules have their 
effect at the sub nanomolar range in leukemic CLL cells but significantly do not affect the 
healthy B cells, Complete cell kill was not achieved in healthy B cells at the highest 
concentration (10µM) indicating specificity of the small molecules to CLL cells. Table 4 
tabulates the LC50 values from different cell types.  
Figure 11: Dose dependent cytotoxicity of GP049090 and PKF115-584 in CLL cell 
lines. JVM-3 cell line (A) and MEC-1 Cell line (B) were incubated with different 
concentrations of the two small molecule inhibitors for 24h and survival was measured 
using a luminescent ATP cell survival assay. The % cell survival is shown as the ratio of 
the DMSO vehicle control. The experiment was repeated three independent times 
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Table 4:   LC50 of PKF115-584 and CGP049090 in different cell types in B-CLL 
Cell Type (n) LC50 PKF115584 (µM)  LC50 CGP049090 (µM) 
JVM-3 cell line (3) 0.93±0.12 0.42±0.2 
MEC-1 cell line (3) 0.49±0.03 0.12±0.05 
Primary CLL cells (24) 0.77 ±0.13 0.89±0.07 
Healthy B cells (3) 5.7±0.04(estimated) 8.5±0.05(estimated) 
 
4.3.3. Patient Sample Characteristics 
 
Peripheral blood samples were  obtained from patients who were previously diagnosed 
for CLL according to standard criteria (Cheson et al. 1996) Table 5 shows the patient’s 
clinical characteristics in terms of their prognostic factors including ZAP-70 and CD38 
expression and % apoptotic  induction by the two inhibitors derived from the in vitro 
cytotoxicity assay. The results indicate that both CGP049090 and PKF115-584 invoke 
heterogeneous cytotoxic responses which are not correlative to any of the prognostic markers 
Figure 12: In vitro cytotoxicity of CGP049090 and PKF115-584 in primary CLL cells 
and Healthy B cells. Primary B-CLL cells (n=24) and Normal B cells from healthy 
volunteers (n=3) were incubated at different concentrations (10, 1, 0.1, 0.01µM) for 24h. 
The % cell survival is shown as the ratio of the DMSO vehicle control. The experiment 
was repeated three independent times and the the results are presented as the Mean ± SE. 
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Table 5: In vitro cytotoxicity of B-CLL samples to CGP049090 and PKF115-584 
Patient ID 
ZAP70 / CD38 
Status* 
Binet 
Stage† 
% Cell Kill at 1 µM 
CGP049090 PKF115-584 
17 NA NA 54 51 
18 ZAP70־/ CD38־ A 45 10 
19 ZAP70־/ NA NA 64 67 
20 ZAP70+/ NA NA 53 75 
21 ZAP70־/ CD38+ B 55 60 
22 ZAP70־/ CD38־ NA 32 74 
23 NA / NA NA 73 62 
24 ZAP70־/ CD38+ B 60 50 
25 NA / NA NA 54 44 
26 NA / NA NA 50 29 
27 ZAP70־/ CD38־ C 42 38 
28 ZAP70+/ CD38־ A 71 71 
29 ZAP70־/ CD38־ A 31 14 
30 ZAP70־/ CD38־ C 53 58 
31 NA / NA B 41 31 
32 ZAP70־/ CD38־ B 40 56 
33 ZAP70־/ CD38־ B 91 88 
34 ZAP70־/ CD38־ A 45 52 
35 ZAP70־/ CD38+ B 88 88 
36 ZAP70־/ CD3  ־  A 47 42 
37 ZAP70־/ CD38+ B 55 56 
38 ZAP70־/ CD38+ B 70 60 
39 ZAP70־/ CD3  ־  B 95 98 
40 NA / NA A 56 45 
  Mean ± s.e. 56.8 ± 4.0 54.9 ± 3.9 
 
*ZAP70 and CD38 expression was determined by flow cytometry. Cells expressing >20% 
ZAP70 and >30% CD38 were considered positive. †Patients classified according to Binet 
staging system indicating progressiveness of the disease. NA represents data not available at 
the time of completion of the study. The % cell kill at 1 µM calculated from the normalized 
(vehicle control) raw data. 
 
4.3.4. CGP049090 & PKF115-584 induces apoptotic cell death in B-CLL 
To verify that both inhibitors CGP049090 and PKF115-584 induce apoptotic cell death, 
primary CLL and JVM-3 cell lines were incubated with 5 µM of the inhibitors for 16 hours. 
Protein extracts were made and the levels of cleaved poly (ADP-ribose) polymerase (PARP) 
were detected by immunoblotting (Figure 13). PARP is DNA repair enzyme involved in 
repairing single strand DNA nicks. However upon induction of apoptosis PARP is cleaved in 
by active caspase-3. This cleavage is intracellular marker of activation of apoptotic 
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machinery. Figure 13 shows increase in accumulation of 89 kDa cleaved PARP in the CLL 
and JVM-3 cell lines following 16 hour incubation. Altogether the cytotoxicity induced by 
these inhibitors is mediated by apoptotic mechanisms  
4.3.5. CGP049090 & PKF115-584 induced apoptotic cell death is dependent 
on activation of caspase pathway 
 
Apoptosis is a tightly regulated death pathway which includes activation of cysteine 
proteases of the caspase family. Caspases exist as inactive pro-caspases but upon apoptotic 
induction is cleaved in to its active form whereby it then cleaves several intracellular targets.  
These are characterized by the cleavage of specific substrates after an aspartic residue, and 
considered essential in the execution stage of the apoptotic process (Fadeel et al. 2000). To 
distinguish if the inhibitors induced apoptosis was driven through the intrinsic or extrinsic 
pathway activation status of two apical proteases caspase-8 and caspase-9 were examined 
along with downstream effectors proteases caspase-3 and caspase-7 (Figure 14).  
Figure 13: Analysis of PARP cleavage upon incubation with CGP049090 and PKF115-
584. Primary CLL cells (A) and JVM-3 cell line (B) were treated with 5µM of the 
inhibitors for 16 hours and the cell lysates were immunoblotted for anti cleaved PARP 
antibody. β-actin was used as the loading control. This observation was confirmed in 
three independent experiments 
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Caspase activation was assessed on the basis of reduction or disappearance of pro-caspases on 
western blot analysis.  To avoid the heterogeneity seen in primary CLL cells derived from 
different donors, the JVM-3 cell line was used as a model system to enumerate the apoptotic 
mechanism involved. Time course experiments on JVM-3 cells treated with 10µM of the 
inhibitors for 6, 12, and 24 hours. Subsequent immunoblotting of whole cell extracts revealed 
cleavage of apical caspases 9 leading to consequent activation of effector caspases 3 and 7, 
which cleave several cellular targets promoting apoptosis (Figure 14). However there was no 
bid cleavage indicating activation of intrinsic mechanism of apoptosis. These data suggest that 
both PKF115-584 and CGP049090 induce apoptotic cell death in CLL cells. 
 
Figure 14: Caspase activation upon incubation with CGP049090 and PKF115584. 
JVM-3 cells were cultured with 10µM of the inhibitors for the indicated time points. 
Lysates were subjected to immunoblot analysis by using specific antibodies for caspase 8, 
9, 3 and 7. β actin was used the loading control. This observation was confirmed in three 
independent experiments. 
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4.3.6. CGP049090 & PKF115-584 suppress the expression of anti-apoptotic 
proteins 
 
B-CLL is a disease which is linked to aberrant expression of anti-apoptotic proteins 
such as Bcl-2, Mcl-1 and XIAP (Kitada et al. 1998). To determine whether CGP049090 and 
PKF115-584 induced apoptosis is modulated by anti apoptotic proteins, JVM-3 cells were 
cultured in the presence of the inhibitor for 6 12 and 24 hours and the lysates were analyzed 
by western blot. Western blotting analysis (Figure 15) reveals that the exposure of the cells 
with the inhibitors steadily decreases XIAP and Bcl-2 proteins. However there was a dramatic 
decrease in the levels of Mcl-1 in the time course experiments. These observations indicate 
that the inhibitors hasten the apoptotic mechanism by down regulating Inhibitors of Apoptosis 
Proteins (IAPs) proteins. 
 
 
 
 
Figure 15: CGP049090 and PKF115584 down regulates anti-apoptotic proteins. 
JVM-3 cells were cultured with 10µM of the inhibitors for the indicated time points. 
Lysates were subjected to immunoblot analysis by using specific antibodies for Mcl-2, 
XIAP and Bcl-2.  β -actin was used the the loading control. This observation was 
confirmed in three independent experiments. 
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4.3.7. β-catenin levels are down regulated upon initiation of apoptosis by 
CGP049090 and PKF115-584 
 
β-catenin has been shown to perform two apparently unrelated functions: it has a 
crucial role in cell–cell adhesion in addition to a signaling role as a component of the Wnt 
pathway. Furthermore it is evident that β-catenin is an important protein which have several 
putative regulators involving in cell proliferation and adhesion (Morin & Weeraratna 2003). It 
was interesting to know the fate of β-catenin upon CGP049090 and PKF115-584 incubation. 
So we treated JVM-3 cell line with the inhibitors for 6 hours, and the total cell extracts were 
immunoblotted for β-catenin (Figure 16). There was a complete reduction of β-catenin upon 
incubation with both the inhibitors when compared to the vehicle control. This is attributed to 
the fact that β-catenin is an important intracellular target of caspase-3 which leads to its 
cleavage and reduces its transactivation potential upon apoptotic induction (Steinhusen et al. 
2000) . 
 
 
 
 
Figure 16: Reduction of β-catenin levels upon apoptotic induction. JVM-3 cells were 
cultured with 10µM of the inhibitors for 6 hours. Lysates were subjected to immunoblot 
analysis by using specific antibody for β-catenin. β -actin was used the the loading 
control. This observation was confirmed in three independent experiments. 
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4.4. CGP049090 and PKF115-584 inhibit the interaction between LEF-1/β-
catenin 
A Previous study on PKF115-584 and CGP049090 pin point that both lead compounds 
specifically inhibit the LEF-1/β –catenin interaction in several in vitro and in vivo assays 
(Lepourcelet et al. 2004). We further tested the potency of these substances to inhibit this 
interaction in CLL cells. Since there was rapid induction of apoptosis on in vitro culture, we 
incubated the inhibitors ex-vivo with the CLL lysates. 10 µM of the inhibitors was incubated 
with total protein extracts from CLL patients for 16 hours along with the vehicle control. Co-
immunoprecipitation was carried out using β–catenin as the precipitating antibody. The 
immuneprecipitate was later subjected to western blot analysis to detect LEF-1(Figure 17). 
The results reveal reduced precipitation of LEF-1 in the lysate incubated with CGP049090 or 
PKF115-584. Vehicle control (0.02% DMSO) also served as the positive control for the 
 
 
Figure 17: CGP049090 and PKF115-584 specifically inhibit co-immunoprecipitation of 
β-catenin and LEF-1. Total cell protein extracts from primary CLL cells were incubated 
with 10 µM of CGP049090 or PKF11584 for 16h at 4°C and later immunoprecipitated 
with β-catenin antibody. The immunoprecipitation was probed for lef-1 and β-catenin by 
immunoblotting. The results reveal reduced precipitation of lef-1 in the lysate incubated 
with CGP049090 or PKF115-584. This observation was confirmed in three independent 
experiments. 
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interaction. Starting extract is denoted as cell lysate (1/30). IgH is the immunoglobulin heavy 
chain of the precipitating antibody. This observation was confirmed in three independent 
experiments  
4.4.1. CGP049090 and PKF115-584 down regulate LEF-1/β-catenin target 
genes in Primary CLL cells 
 
Since both the inhibitors specifically inhibit the LEF-1/β-catenin interaction, it is likely 
that there should be an inhibition of LEF-1 transcribed target genes. To investigate whether 
the resulting apoptosis is mediated by paralleled down regulation of LEF-1 target genes we 
treated primary CLL cells (n=3) with 5 µM of the inhibitors for 48 hours. The resulting total 
cell lysate was immunoblotted for detecting c-myc, cyclin D1 and LEF-1 (Figure 18). 
 
 
 
Figure 18: CGP049090 and PKF115-584 specifically inhibit LEF-1 target genes 
expression. Total cell protein extracts from primary CLL cells were incubated with 5µM 
of CGP049090 or PKF11584 or the vehicle control (0.01% DMSO) for 48 hours. The cell 
lysates were immunoblotted and probed for lef-1, β-catenin, c-myc and cyclin D1. The 
results reveal there is a concordant downregulation of lef-1 target genes in the lysate 
incubated with CGP049090 or PKF115-584. This observation was confirmed in three 
different primary CLL samples. 
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As expected, there was a reduction of LEF-1 target genes in all the three CLL samples 
confirming the fact that CGP049090 and PKF115-584 down regulate LEF-1 target genes and 
are fairly specific in their activity. Furthermore there was also a down regulation of β-catenin 
due to apoptotic induction as described earlier in JVM-3 cell lines. 
4.4.2. CGP049090 and PKF115-584 down regulate LEF-1/β-catenin target 
genes in JVM-3 cell lines 
 
The down-regulation of LEF-1 target genes was also confirmed in the JVM-3 cell lines. 
The cells were treated with 5 µM of the inhibitors for 24 hours. The protein extract was 
immunoblotted for c-myc, cyclin D1, LEF-1 and β-catenin. There was down-regulation of 
LEF-1 target genes and reduction of β-catenin (Figure 19). This observation was confirmed in 
3 independent experiments. 
 
 
Figure 19: CGP049090 and PKF115-584 specifically inhibit LEF-1 target genes 
expression in JVM-3 cells. Total cell protein extracts from JVM-3 cell lines were 
incubated with 5 µM of CGP049090 or PKF11584 or the vehicle control (0.02% DMSO) 
for 24 hours. The cell lysates were immunoblotted and probed for lef-1, β-catenin, c-myc 
and cyclin D1. The results reveal there is a concordant downregulation of lef-1 target 
genes in the lysate incubated with CGP049090 or PKF115-584. This observation was 
confirmed in three independent experiments. 
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4.4.3 Apoptosis induced by CGP049090 and PKF115-584 is inhibited by Pan 
Caspase inhibitors ZVAD.FMK 
 Caspases exhibit highly conserved catalytic and substrate recognition motifs. This 
allows amino acid sequences (ZVAD) to interact with both positive and negative regulators of 
their activity. The feature has been exploited in the generation of peptides that compete for 
caspase binding  (Cryns & Yuan 1998). Fluoromethyl ketone (FMK)-derivative peptides act 
as effective irreversible inhibitors with no added cytotoxic effects. These pan caspase 
inhibitors successfully inhibit their activity in vivo and in vitro (Guo & Kyprianou 1999). We 
used pan caspase inhibitors to determine a) whether the apoptosis induced by CGP049090 and 
PKF115-584 is inhibited by pre-treatment with ZVAD-fmk b) to determine whether the IAPs 
and lef-1 target proteins are down regulated preceding or succeeding caspase activation. We 
treated primary CLL cells with 3 µM of inhibitors for 16h in the presence or absence of 50 
µM pan caspase inhibitor (ZVAD-fmk) with respective vehicle control for 16h. Pre treatment 
of CLL cells with pan caspase inhibitors lead to inhibition of caspase 3 and PARP cleavage 
confirming the cell death induced by the small molecule inhibitors is arrested  in the presence 
of pan caspase inhibitors (Figure 20). 
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4.4.4 Apoptosis induced by CGP049090 and PKF115-584 leads to cleavage of 
LEF-1 target proteins 
The rapid onset of apoptosis also raises the question whether the downregulation of 
LEF-1 target genes precedes apoptosis as previously observed. However the results from the 
caspase inhibition experiments reveals that there was no complete down regulation of anti 
apoptotic proteins (XIAP, Mcl-1) and LEF-1 target genes (LEF-1, c-myc, and cyclin D1) in 
the presence of pan caspase inhibitors. (Figure 21). This leads to the conclusion that the 
CGP049090 and PKF115-584 induced caspase mediated proteolytic cleavage is responsible in 
Figure 20: CGP049090 and PKF115-584 induced apoptosis in inhibited by pan caspase 
inhibitors. Primary CLL cells were incubated with 50µM of pancaspase inhibitoirs for 1 
hour followed by 5 µMCGP049090 or PKF11584 or the vehicle control (0.4% DMSO) for 
16 hours. The cell lysates were immunoblotted and probed for cleaved PARP and caspase 
3 with actin as loading control. The results reveal there is inhibition of PARP cleavage 
and caspase 3 cleavage in the lanes treated with pancaspase inhibitors (+) when 
compared to lanes without pancaspase inhibitors (-). This observation was confirmed in 
two independent experiments. 
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general degradation of cellular proteins rather solely on LEF-1 mediated downregulation in 
vitro. 
 
 
 
4.5. Enhanced auto-fluorescence exhibited by PKF115-584 
Both the inhibitors had considerable auto-fluorescence properties due to their 
heterocyclic carbon rings in their molecular structure. But PKF115-584 displayed enhanced 
auto-fluorescent properties which could be used in localization studies. Briefly 5x106 primary 
B-CLL cells were treated with 5µM of PKF115-584 for 6 hours. Cell were then washed in 
twice in PBS and resuspended in a final volume of 200µl of PBS. Cells were later fixed on to 
Figure 21: CGP049090 and PKF115-584 induced apoptosis cleaves several 
intracellular target proteins. Primary CLL cells were incubated with 50µM of pancaspase 
inhibitoirs for 1 hour followed by 3 µMCGP049090 or PKF11584 or the vehicle control 
(0.4% DMSO) for 16 hours. The cell lysates were immunoblotted and probed for LEF-
1target genes (lef-, cmyc, cyclin D1) IAPs (XIAP, mcl-1) and β catenin. The results show 
cleavage of all of the indicated proteine in the lanes without pancaspase inhibitors (-) 
when compared to lanes treated with pancaspase inhibitors (+). This observation was 
confirmed in two independent experiments.. 
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the slides immersed in ice cold ethanol and mounted with DAPI mounting medium. 
Fluorescence microscopy was used to capture nuclear DAPI at excitation wavelength of 
350nm and PKF115-584 at excitation wavelength of 536nm. Figure 22A shows the merged 
images indicating the localization of PKF115-584 in the CLL cells at 200X magnification. 
PKF115-584 is mostly predominantly localized in the cytosol and not in the nucleus. Figure 
22B shows an inset of figure 22A revealing formation of condensed nuclei (dotted arrow) and 
apoptotic bodies (continuous arrow) in cells undergoing apoptosis at 1000X magnification. 
 
 
4.5.1. LEF-1 Overexpression and Intracellular Co-localization with PKF115-
584 in CLL Cells. 
 
Of the two inhibitors tested PKF115-584 had substantial auto fluorescence properties. 
Next we decided to treat the cells with PKF115-584 for 3 hours and lable LEF-1 by indirect 
immunofluorscence. Results of indirect immunofluorescence studies revealed a high 
Figure 22: Intracellular localization of PKF115-584 expression. Primary CLL cells 
were incubated with 5µM of PKF115-584 for 6 hours. The cells were fixed and 
counterstained with DAPI and later subjected to fluorescence analysis. A) Shows DAPI 
stained nuclei (blue) and localization of PKF115-584 (red) B) an inset of (A) showing 
apoptotic blebs (arrow) and condensed nuclei (dotted arrow) 
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expression of LEF-1 in both, the cytoplasm and nucleus in primary CLL cells. PKF115-584 
had a strong cytoplasmic localization during apoptosis, implying that the inhibition occurs in 
the cytoplasmic level at LEF-1 or β-catenin. Figure 23 shows the independent and merged 
channels of a CLL cell treated with PKF115-584 for 3h and labeled with FITC lef-1 antibody 
and nucleus stained in DAPI. The yellow region in the cytoplasm of the merged picture 
represents co-localization of lef-1and PKF115-584, suggesting possible inhibition of lef-1 
transport into the nucleus by the inhibitors. 
 
 
4.6. In Vivo efficacy of CGP049090 and PKF115-584 in pre-clinical mouse 
model.  
Many of the lead substances involved in drug discovery fail to make in to the pre-
clinical and clinical trial phase mostly due to lack of convincing pharmacokinetic and 
toxicological properties. Hence it is essential to test these inhibitors in a suitable in vivo 
Figure 23: Co-localization of PKF115-584 and LEF-1. 5x106 primary CLL cells were 
incubated with 5µM PKF115-584 for 3h. The cells fixed and incubated with primary 
antibody (LEF-1 or isotype control) for 60 min. Cells were later incubated with secondary 
FITC labeled antibody for 30min. Cells were applied to ethanol rinsed microscopic glass 
slides, air dried counterstained by DAPI. Images were acquired by fluorescence 
microscopy. 
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mouse model to elucidate the response in an in vivo setting. The in vivo efficacy studies of 
CGP049090 and PKF115-584 were carried in a JVM-3 subcutaneous xenograft nude mouse 
tumor model. 
4.6.1. CGP049090 and PKF115-584 inhibit tumor growth in vivo 
 
We first investigated the in vivo efficacy and systemic tolerance to the inhibitors in a 
small cohort of mice (n=4). JVM-3 cell lines were injected subcutaneously in the athymic 
nude mice and the tumor growth was monitored for a week. When the tumor volume reached 
a minimum of 80mm3, the mice were divided into 3 groups (4 mice per group) and treated 
intraperitoneally with 25mg/kg of CGP049090, PKF115-584, or the vehicle control every 
other day for 5 doses. The tumor volume was measured prior to therapy and every third day 
after initiation of therapy. Figure 24 shows the tumor growth response following 
administration of 5 doses at 25mg/kg over a period of 12 days after initiation of therapy. 
There was a significant cessation of tumor growth in the mice treated with CGP049090 and 
PKF115-584. 
Table 6 shows this observation in terms of the tumor inhibitory rate (IRmax) and the 
rate of body weight reduction (∆BWmax). The ∆BWmax in the vehicle treated group is was 
slightly elevated due to the tumor load in the animals. All of the mice in the treated group 
survived the course of the therapy and the observation period. Both small molecule inhibitors 
exert their activity specifically on tumor cells without affecting the normal tissues. 
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Figure 24: CGP049090 and PKF115-584 inhibit tumor growth in vivo. Tumor volume in 
mice (n=four/group) treated with CGP049090 or PKF115-584 following administration of 
5 doses at 25mg/kg over a period of 12 days after initiation of therapy. There was a 
significant cessation of tumor growth in the mice treated with both CGP049090 and 
PKF115-584 inhibitors. 
Table 6. Therapeutic effect and systemic toxicity of CGP049090 and PKF115-584 
(25mg/kg) in JVM-3 xenografts in nude mice. IRmax indicates the greatest effect of each 
test inhibitor. ∆BW is the rate of body weight reduction. The maximal value for ∆BW was 
designated as ∆BWmax, from which each test compound’s toxicity to mice was evaluated. 
*Mean±s.e. † p<0.05 
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4.6.2. CGP049090 and PKF115-584 increases the median survival of the 
treated mice 
The previous experiment was repeated in a larger cohort of mice (n=8 per group) and 
treated with a higher dose of 25mg/kg bodyweight for 12 days and tumor volume and survival 
was observed for 30 days. The tumor volume was measured every third day and mice which 
reached a maximum tumor volume of 1000mm3 were removed from the study and euthanized 
due to ethical reasons. The day of euthanization due to the enlarged tumor volume was 
considered as a death event for Kaplan-Meier survival analysis. Figure 25 shows the Kaplan-
Meir analysis of CGP049090 and PKF115-584 treated mice compared to the control.  
Kaplan-Meier survival curves reveal that treatment significantly improves median 
survival by 12.5 days (p= 0.003) with CGP049090 and 15.5 days (p=0.0023) with PKF115-
584. These data suggest that both the both the inhibitors have a respectable tendency to inhibit 
tumor growth and extend the survival in the control group. 
 
 
 
 
 
 
 
 
 
 
Figure 25: CGP049090 and PKF115-584 increases the median survival of the treated 
mice. The survival benefit conferred to the group treated with CGP049090 was 12.5 days 
(p=0.003) and 15.5 days (p=0.0023) with the group treated with PKF11-584 when 
compared to the group treated with vehicle only.  
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4.6.3. Tumor growth cessation by CGP049090 and PKF115-584 in vivo is 
mediated by inhibition of cellular proliferation and apoptosis 
 
We could demonstrate that both small molecule inhibitors inhibit tumor cell 
proliferation in the pre-clinical JVM-3 xenograft mouse model. Figure 25 shows the visual 
tumor growth in a representative mouse of each group.  The mice treated with the vehicle 
shows an enlarged subcutaneous tumor (A) whereas the mice treated with CGP049090 and 
PKF115-584 show a smaller tumor with a central red necrotic patch indicative of cellular 
termination (B & C). 
 
 
 
 
 
 
Figure 26: CGP049090 and PKF115-584 inhibit in vivo tumor growth. After 6 doses of 
therapy (25mg/kg) a representative mouse from each group was inspected for tumor 
growth. The vehicle treated mice (A) shows an enlarged tumor without central area of 
necrosis, whereas mice treated with the respective inhibitors (B & C) show a reduced 
tumor with a central necrosis indicative of cell death at the central regions of the tumor 
due to the therapy 
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4.6.4. LEF-1 is downregulated upon treatment with CGP049090 and 
PKF115-584 in vivo 
 
To understand the mechanism of inhibition of CGP049090 and PKF115-584 in vivo 
paraffin embedded tumor sections were made from the tumors derived from the vehicle 
control, CGP049090 and PKF115584 for immunohistochemistry analysis. 
Immunohistochemical staining using LEF-1 antibody revealed that there was a distinct 
downregulation of LEF-1 in the treated samples when compared to the vehicle control. Figure 
26 shows uniform LEF-1 expression in the vehicle treated control, whereas sporadic 
expression in the treated samples. This indicates that both small molecule inhibitors function 
in an expected manner by targeting LEF-1 expression in vivo. 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: CGP049090 and PKF115-584 inhibit LEF-1 expression in vivo. After 12 
doses of therapy (25mg/kg) a representative mouse from each group was sacrificed and the 
tumor was used to generate paraffin embedded sections and subsequently labeled for LEF-
1 by immunohistochemistry. The vehicle treated mice (Control) shows uniform expression 
of LEF-1 when compared to the sporadic expression  seen in mice treated with 
CGP049090 and PKF115-584. 
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4.6.5. In Vivo Inhibition of Proliferation (PCNA) and Increase of Apoptosis 
(cleaved PARP) after CGP049090 and PKF115-584 treatment. 
 
In order to distinguish the mode of cell death from apoptosis and necrosis due to 
possible acute toxicity of the inhibitors in vivo, paraffin embedded tumor sections were made 
from the tumors derived from the vehicle control, CGP049090 and PKF115584 for 
immunohistochemistry analysis. Proliferating Cell Nuclear Antigen (PCNA) is a member of 
the DNA sliding clamp family of proteins that assist in DNA replication and acts as a co-
factor for DNA polymerase delta (Kelman & O'Donnell 1995). PCNA is expressed in the 
nuclei of cells during the DNA synthesis phase of the cell cycle and hence considered as a 
marker for proliferation (Leonardi et al. 1992). The immunohistochemical analysis revealed 
that PCNA expression was completely inhibited in the mice treated with CGP049090 and 
PKF115-584 when compared to the vehicle control. This indicates that the cells in the treated 
group are not in an active state of proliferation due to the treatment with the small molecule 
inhibitors (Figure 27A). 
On the other hand to reveal the inhibition of cell proliferation resulted in apoptotic cell 
death the tumor sections were probed for the presence of cleaved PARP by 
immunohistochemistry. As mentioned earlier PARP, a 116kDa nuclear poly (ADP-ribose) 
polymerase, appears to be involved in DNA repair in response to environmental stress (Satoh 
& Lindahl 1992). This protein is one of the main cleavage targets of caspase-3 in vivo. In 
human PARP, the cleavage occurs between Asp214 and Gly215, which separates the PARP 
amino-terminal DNA binding domain (24kDa) from the carboxy-terminal catalytic domain 
(89kDa) (Nicholson et al. 1995) hence cleavage of PARP facilitates cellular disassembly and 
serves as a marker of cells undergoing apoptosis. The immunohistochemical analysis reveal  
that there was no cleaved PARP detectable in the control tumor sample but increased 
incidence of cleaved PARP in the  mice treated with CGP049090 and PKF115-584. This 
indicates that cells in the treated group are undergoing apoptotic cell death (Figure 27B). 
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Figure 28: CGP049090 and PKF115-584 inhibit proliferation and increase apoptosis in 
vivo. After 12 doses of therapy (25mg/kg) a representative mouse from each group was 
sacrificed and the tumor was used to generate paraffin embedded sections and 
subsequently labeled for PCNA (A) as marker of proliferation and Cleaved PARP as 
marker for apoptosis (B) by immunohistochemistry. There was a decrease in PCNA 
expression and increased cleaved PARP in mice treated with CGP049090 and PKF115-
584. 
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5. Discussion 
The concept of translational research has received very strong focus in the biomedical 
community over the last few years, as a new way of thinking and conducting life science 
research to accelerate healthcare outcomes. According to NCI definition (National Cancer 
Institute, USA), ‘Translational research transforms scientific discoveries arising from 
laboratory, clinical, or population studies into clinical applications to reduce cancer incidence, 
morbidity, and mortality.(2009). Hence there is a constant need for rendering the findings of 
basic research to into clinical application. This study is one such attempt to translate findings 
from basic research into clinical relevance. 
Chronic lymphocytic leukemia (CLL) is a disease characterized by accumulation of 
dysfunctional B-cells with significant resistance to apoptosis, thereby enhancing their survival 
in vivo (Dighiero & Binet 2000). As CLL is not driven by a single genetic variation, targeting 
intracellular proteins would be an interesting therapeutic approach. Understanding the 
pathogenesis of this disease would unravel critical therapeutic targets. Among the signaling 
pathways involved in the manifestation of the B CLL, the Wnt pathway is a major signaling 
system that is constitutively turned on in B CLL cells leading to expression of several genes 
involved in survival. 
Much of the understanding about Wnt signaling has been primarily derived from lower 
organisms such as drosophila, C.elegans and xenopus embryos. The Wnt pathway is a critical 
determinant of cell proliferation during early development and regenerative processes, 
whereas its completely switched off in mature cellular phenotypes except stem cells in the 
adults (Clevers 2006). Aberrant activation of the Wnt pathway has been linked to oncogenesis 
in multiple systems usually involving gain/loss of function mutations of different proteins of 
the pathway (Janssens et al. 2006). In CLL aberrant expression of Wnt ligands and epigenetic 
alterations of physiological Wnt inhibitors has been implicated in the extended survival of 
CLL cells in vivo (Lu et al. 2004; Chim et al. 2008). Moreover LEF-1 the transcription factor 
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which is highly over-expressed exclusively in CLL cells has been overlooked regarding its 
role in transcriptional significance in the overall survival of CLL cells. There are currently no 
reports on the role of LEF-1 in survival of CLL cells. The purpose of this study is to 
determine the role LEF-1 in the survival of CLL cells and validate it as a therapeutic target 
using the novel LEF-1/β-catenin small molecule inhibitors CGP049090 and PKF115-584. 
5.1. Expression of LEF-1 and β-catenin in CLL 
Previous reports have indicated the indicated the high LEF-1 expression in mRNA 
levels but there are no reports on actual expression levels at the protein level (Klein et al. 
2001; Howe & Bromidge 2006). Hence we first set to examine the endogenous basal 
expression of LEF-1 in primary B-CLL cells when compared to healthy B cells at the protein 
level. LEF-1 was consistently and highly expressed in CLL cells but completely undetectable 
in healthy B cells. B-CLL cells also express short isoform of LEF-1 with the β-catenin 
binding domain derived from an intronic promoter. However the shorter isoform without the 
β-catenin binding domain cannot function in transcription activity in the nucleus (Hovanes et 
al. 2001). The peripheral blood mononuclear cells (PBMCs) express restrained amount of 
LEF-1 as they are expressed in T cell compartments (Travis et al. 1991). However the JVM-3 
and MEC-1 cell lines cells do not express similar levels of LEF-1 as the primary CLL cells 
since these cell lines are prolymphocytic cell lines and do not represent the true CLL 
characteristics (Figure 6). These findings are coherent with previous studies undertaken at the 
mRNA levels. 
β-catenin is essential for LEF-1 transactivation however, we could observe a steady 
detectable pool of both phosphorylated and de-phosphorylated forms of β-catenin. The 
maintenance of de-phosphorylated β-catenin is attributed to autocrine (Wnt ligands) and 
paracrine action (microenvironment) (Caligaris-Cappio 2003; Ghia et al. 2002). Upon BCR 
ligation, activation of PI3K/Akt pathway which inhibits gsk3-β in the CLL cells, also leads to 
stabilization of de-phosphorylated β-catenin (Christian et al. 2002). 
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On the other hand, the grounds for the overexpression of LEF-1 in CLL have not yet 
been identified. Wnt signaling can promote the expression of several Wnt pathway 
components, indicating that feedback control is a key feature of Wnt signaling regulation. One 
could speculate that any loss in one or several of these feedback loops could contribute to the 
overexpression of LEF-1 in leukemic B cells. 
Moreover, the functional significance of LEF-1 and β-catenin is only complete when 
both of the proteins are localized in the nucleus involving in transactivation of target genes. 
Figure 7 shows that LEF-1 (short and long forms) is predominantly localized in the nucleus 
along with β-catenin indicating active LEF-1/ β-catenin transcriptional co-activation. 
Hence the aberrant activation of Wnt signaling is in cooperation with massive 
expression of LEF-1 and a steady pool of de-phosphorylated β-catenin in primary CLL cells. 
5.2. LEF-1 and B-CLL survival 
Since LEF-1 is over-expressed in CLL and has several target genes to be involved in 
survival and proliferation (Table 1) it is expected that they have a vital role to in survival of 
CLL cells. siRNA mediated LEF-1 knockdown experiments in primary CLL cells resulted in 
increased apoptosis in CLL cell which directly implies the important role of LEF-1 in CLL 
survival. One major drawback in this approach is the that primary CLL cells undergo 
spontaneous apoptosis upon in vitro culture (Collins et al. 1989) and is a major hurdle in 
performing functional experiments in vitro in CLL cells (Seiffert et al. 2007). This has led to 
poor transfection efficiencies (max 25%) and poor viability post transfection as seen from 
figure 9. Nevertheless there was a statistically significant change in cell survival upon siRNA 
mediated LEF-1 inhibition. To further understand role of LEF-1 in B-CLL cells we 
transfected JVM-3 cell lines with LEF-1 siRNAs. Interestingly, the there was a decrease of 
LEF-1 target genes (c-myc, cyclin D1) but no PARP or β-catenin cleavage at 72 hours. This 
indicates that there was no initiation of apoptosis upon LEF-1 inhibition in JVM-3 cell line. 
But there was decrease in PCNA expression which is widely considered as a proliferation 
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marker indicating growth arrest in the cell line. The difference in the outcome (apoptosis Vs 
growth arrest) of siRNA mediated LEF-1 inhibition in primary CLL cells and cell lines is that 
the primary CLL cells are already in G0 cell cycle arrest and are mostly non proliferative 
(Hamblin & Oscier 1997), whereas JVM-3 cell lines are EBV transformed and are in high 
proliferative rate (Melo et al. 1988). But in either of cases the LEF-1 knockdown leads to 
apoptosis in resting CLL cells or leads to growth arrest in JVM-3 cell lines indicating the 
clinical importance of targeting LEF-1 signaling in CLL cells. Thus LEF-1 might represent a 
promising therapeutic target in CLL belonging to both the subgroups of CLL. 
5.3. In vitro Efficacy of CGP049090 and PFK115-584 CLL 
Both CGP049090 and PKF115-584 are known to inhibit TCF/LEF-1/β-catenin 
interaction (Lepourcelet et al. 2004). It was most interesting to test the efficiency of these 
inhibitors in B-CLL model due to the over-expression of LEF-1. The dose response curves 
generated showed similar results in CLL cell lines (MEC-1 and JVM-3) and primary CLL 
cells. The LC50 was less than 1µM in the cell lines tested leading to a complete cell kill at the 
highest tested concentration (10µM). Similarly treating 24 heterogeneous primary CLL 
samples we determined the LC50 to be 0.89µM for CGP049090 and 0.77µM for PKF115-
584. LC50 values fall in the same range as in the previous studies, which tested these 
inhibitors in colon carcinoma, prostate cancer and multiple myeloma cell lines (Lepourcelet et 
al. 2004; Lu et al. 2004; Sukhdeo et al. 2007). It has to be noted that another study attempted 
the same in CLL using the β-catenin-inhibitor R-etodolac which was unsuccessful due to its 
high LC50 for more than 250µM (Lu et al. 2004). Similarly, another novel etodolac SDX-
308, tested in multiple myeloma cells was found to target the TCF/LEF-1/ β-catenin pathway 
but the LC50 values were more than 30µM and was not tested in vivo. 
The % cell kill at 1µM (Table 5) showed variable cytotoxcity and no correlation to the 
prognostic factors which indicates that the inhibitors have their cytotoxic effects in both 
subsets of CLL.  
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The foremost importance of any targeted therapy is that the healthy counterparts are 
spared from the cytotoxic activity. Hence we tested these compounds in purified B cells from 
healthy volunteers. Interestingly healthy B cells were not affected as 10µM was not enough to 
achieve the same complete cell kill as observed in leukemic cells. The estimated LC50 was 
5.7µM for PKF115-584 and 8.5µM for CGP049090 respectively. Furthermore these inhibitors 
do not affect the healthy PBMCs as seen from the estimated LC50 values of 37.83µM and 
113.31µM for PKF115-584 and CGP049090, shown previously by our group (Minke et al. 
2009).  
Since both CGP049090 and PKF115-584 are heterocyclic compounds they exhibited 
pronounced auto-fluorescence properties. We utilized this property in PKF115-584 to localize 
the drug in the cell with respect to LEF-1. As observed earlier in western blots (Figure 7) we 
could see LEF-1 expression in both cytoplasm and in the nucleus which was confirmed by 
immunofluorescence studies (Figure 23). This concludes that the inhibition of LEF-1/β-
catenin occurs at the cytoplasmic level as PKF115-584 was not localized in the nucleus. 
5.4. Mechanism of apoptotic Induction by CGP049090 and PKF115-584 
CLL is the disease of failed apoptosis. In the present work we show that both small 
molecule inhibitors show pro-apoptotic activity in CLL patient cells and cell lines. Upon 
treatment the CLL cells exhibited all the typical hallmarks of apoptosis, such as activation of 
caspases, cleavage of PARP and membrane blebing. Bcl-2 family of proteins are known to be 
critical regulators of apoptosis and have been implicated in CLL (Packham & Stevenson 
2005). We found moderate down regulation of Bcl-2 upon incubation with CGP049090 and 
PKF115-584. However we observed complete down-regulation of Mcl-1 and XIAP upon 
treatment. Recent study shows that Mcl-1 expression in CLL is correlated with survival and 
chemoresistance in CLL cells (Saxena et al. 2004), hence downregulation of Mcl-1 plays an 
important role in apoptotic induction in CLL cells. XIAP is physiological inhibitor of caspase 
3, 7 and 9 and efficiently inhibits apoptosis (Deveraux & Reed 1999). However upon 
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treatment with CGP049090 and PKF115-584 there is a downregulation of XIAP which 
accelerates the apoptotic process in CLL cells.  
Apoptosis can be initiated by the death-receptor (extrinsic) pathway that acts through 
caspase 8 or mitochondrial (intrinsic) pathway that acts through caspase 9, but both pathways 
converge to activate the effector  caspases (caspase 3), which act on the death substrates 
(Reed 2000). In order to differentiate the mode of apoptotic induction from intrinsic or 
extrinsic pathway we checked for bid cleavage. If the apoptotic signal is from the extrinsic 
pathway, caspase 8 is activated which cleaves bid to tbid (Li et al. 1998). The tbid translocates 
from the cytoplasm into the mitochondria thereby initiating the release of cytochrome C 
which in turn forms a complex with APAF-1 (apoptosis-activating factor 1) which in turns 
activates caspase 9. However the time course experiments on JVM-3 cells indicate that there 
was no significant bid cleavage between 6-12 hours despite caspase 8 cleavage. But during 
the same 6-12 hour time frame we could see a significant cleavage of caspase 9 (Figure 14). 
The active caspase 9 cleaves pro-caspase 3 into it active form which in turn cleaves several 
intracellular targets like PARP and β-catenin. 
However upon cellular stress, by radiation or cytotoxic drugs the cytochrome C is 
released by the intrinsic pathway from the mitochondria which then forms complex with 
APAF-1 leading to subsequent activation of caspase 9 and caspase 3 (Reed 2000). Since there 
was no bid cleavage upon incubation with CGP049090 and PKF115-584, it is obvious that 
these small molecules induce apoptosis through the intrinsic pathway. 
Recently dasatinib, a src kinase inhibitor was found to be only effective in vitro with 
preference for a subgroup of patients with unmutated IgVH genes (Johnson et al. 2006; 
Veldurthy et al. 2008). Since CLL is a heterogeneous disease with different subsets 
determining the prognosis of the disease, our results show that both CGP049090 and PKF115-
584 have similar effects independent of both subsets of CLL tested (ZAP70/CD38) which 
could be advantageous in a clinical perspective. 
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Both inhibitors induce apoptosis in non-proliferative primary CLL cells and an EBV-
transformed CLL cell line, in a dose dependent mechanism indicating that these inhibitors are 
excellent choices for targeting LEF-1 in clinical treatment of the disease. 
5.5 Specificity of the CGP049090 and PKF115-584 
Both substances are known to have higher affinity to inhibit the TCF/LEF-1/ β-catenin 
complexation (Lepourcelet et al. 2004). Co-immunoprecipitation (co-IP) experiments were 
done verify this claim in CLL model. Our study was limited to perform co-IP experiments ex 
vivo on crude total cell protein extracts as there was a rapid induction of apoptosis and a 
steady loss of β-catenin due to caspase activation (Steinhusen et al. 2000). As expected both 
small molecule inhibitors effectively antagonize LEF-1/ β-catenin complex formation in vitro 
confirming previous studies. There are considerable evidences from previous studies that 
these small molecule inhibitors inhibit LEF-1/catenin interaction from 
TOPFLASH/FOPFLASH reporter assays (Sukhdeo et al. 2007; Doghman et al. 2008). 
However our in vitro studies employing pan caspase inhibitors revealed that these small 
molecules inhibitors induced apoptosis preceding down regulation of LEF-1 target proteins in 
CLL cells (Figure 21). This suggests that silencing LEF-1 activity and induction of apoptosis 
are dual properties/events exhibited by both CGP049090 and PKF115-584. This can be 
supported from comparing the results of the siRNA mediated LEF-1 knockdown (Figure 10) 
Versus CGP049090 and PKF115-584(Figure 19) experiments in JVM-3 cell line.  siRNA 
mediated LEF-1 knockdown in JVM-3 cell line  lead to growth inhibition (reduction of 
PCNA, PARP) but no apoptosis in JVM-3 cells, whereas CGP049090 and PKF115-584 
induced apoptosis(cleaved PARP). However the underlying mechanism explaining the 
induction of apoptosis by these inhibitors remains to be elucidated. Current evidences suggest 
that both CGP049090 and PKF115-584 induce cell cycle arrest at G1/S phase (Sukhdeo et al. 
2007).  
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This was also reflected in the downregulation of TCF/LEF-1 target genes in CLL. In 
the present work we have show downregulation of LEF-1 target genes c-myc, cyclin D1 and 
LEF-1 in primary CLL cells as upon incubation with the small molecules. This 
downregulation is due to apoptotic induction rather than complete LEF-1 knockdown as seen 
from figure 21. Nevertheless LEF-1 knockdown experiments in using siRNA in JVM-3 cell 
line indicate downregulation of the target genes (Figure 10) c-Myc is one of the most 
important targets of LEF-1 signaling with respect to malignant diseases. c-Myc is a 
transcription factor which governs the expression of 15% genes in the human genome 
involved in cell division, cell growth, and apoptosis (Dang et al. 2006; Zeller et al. 2003). 
Hence indirect c-myc knockdown deprives the survival advantages of the CLL cells. Another 
study which targeted c-myc in MCF-7 breast tumor cells by siRNAs lead to significant 
inhibition growth of tumor cells in vitro and in vivo (Wang et al. 2005b). 
Cyclin D1 has been disregarded in B-CLL proliferation and its apoptotic block. Very 
little is known about its role in the pathogenesis in CLL, although in some cases, it has been 
used as a prognostic marker in CLL (Faderl et al. 2002).  Hence, cyclin DI downregulation 
must be regarded as a surrogate for LEF-1 inhibition in the context of our work, but no 
statement can be made about its functional relevance. Moreover, further studies are needed to 
examine the complete set of genes which are modulated upon incubation with the inhibitors 
by microarray analysis. 
Although one would expect that the selective leukemic cell killing is directly related to 
inhibition of LEF-1 expression, one has to admit that most of the small molecule inhibitors do 
show off-target effects on cells. However to what extent CGP049090 and PKF115-584 show 
off target effects remains to be elucidated. 
5.6. In vivo efficacy of CGP049090 and PKF115-584 
Despite the promising results in vitro, there are many factors that influence the activity 
of a compound during in vivo applications. Factors such as solubility, bioavailability and 
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toxicity of the drug, play a vital role in the pre-clinical drug development. On the other hand, 
the drug has to overcome the cellular interactions and reactions in the in vivo 
microenvironment which can rescue leukemic cells from cytotoxic agents. For example 
flavopiridol, a cyclin-dependent kinase inhibitor, showed promising results in vitro but failed 
to have any activity in the clinical setting (Flinn et al. 2005).   
To address these issues we first treated a small cohort of non-transplanted mice with 
50mg/kg bodyweight daily of CGP049090 or PKF115-584 for 14 days and ascertained that 
the mice did not develop any gross systemic toxicity (data not shown). This is also consistent 
to a previous study which investigated pharmacokinetics and metabolism of another 
compound, calphostin C, which structurally resembles PKF115-584 (Chen et al. 1999). The 
authors reported that i.p. administration of 40mg/kg bodyweight in CD1 mice resulted in 
therapeutically relevant plasma levels (Cmax = 2.9 µM). Moreover, no toxic signs or fatalities 
could be observed in the animals during a 30 day observation period after administration. 
Although it is always appropriate to test the small molecules in a suitable B-CLL 
mouse model, due to the nature of the disease, there is no single animal model representing 
true CLL characteristics in a mouse model. Although several transgenic mouse models are 
being currently studied to understand the pathogenesis of CLL (Pekarsky et al. 2007), none of 
these models were suitable for testing pre-clinical drugs. Nevertheless we attempted to test 
these inhibitors in a transgenic Eµ-TCL1 model (Johnson et al. 2006) and were highly 
unsuccessful due to unpredictable deaths in both treated and control groups and the extended 
period of time for the Eµ-TCL-1 transgenic mice to develop leukemia. Therefore, owing to 
the lack of a convincing in vivo tumor model for CLL we carried out in vivo studies in JVM-3 
subcutaneous xenografts. The results of the experiments indicated that all of the mice in the 
treated groups survived the entire regimen with a significant tumor inhibition (Figure 24, 26; 
Table 6) and showed extended survival (Figure 25) when compared to the controls regardless 
of high proliferative rate exhibited by the EBV transformed JVM-3 cells. 
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Both substances were well tolerated in vivo, as observed from the ∆BWmax values. 
Interestingly there were no toxicity induced deaths encountered in the animal experiments 
indicating both CGP049090 and PKF115-584 do not show lethal systemic toxicity. Although 
PKF11-584 was tested in vivo in multiple myeloma xenograft model with convincing results, 
but revealed bone marrow hypoplasia due to inhibition of Wnt signaling in hematopoietic 
stem cells which is vital for their self-renewal and proliferative capacity, thereby leading to 
depleted stem cell populations (Sukhdeo et al. 2007). In this present study for the first time 
we showed that CGP049090 also possesses anti-leukemic properties in vivo.  
We set to determine the mechanism of tumor inhibition in vivo. Immunohistochemistry 
analysis of the tumor tissue from the treated and control groups clearly indicate reduced of 
LEF-1 expression in the treated group (Figure 27). This is then reflected in reduced 
proliferation as seen PCNA expression and increase in cleaved PARP (Figure 28A & B) 
indicating ongoing apoptosis. PKF115-584 has been previously demonstrated to block cells 
entering into the S phase of the cell cycle and inducing apoptotic genes (Sukhdeo et al. 2007). 
Our result correlated with this finding, evidenced by the reduced PCNA expression and 
increased apoptosis (PARP cleavage) seen in vivo seen upon treatment with CGP049090 and 
PKF115-584. 
5.7 Off-target effects of CGP049090 and PKF115-584 
Although one would expect that the selective leukemic cell killing is directly related to 
inhibition of LEF-1 expression, the small molecule inhibitors also do show off-target effects 
in the cells. There are recent debates in the scientific community on the need of ‘dirty drugs’ 
that can target multiple proteins in the tumor cell rather than one single target to cure cancer, 
since there are several deregulated pathways in cancer promoting oncogenesis and the cancer 
cells are able to adapt and generate drug resistance (Fojo 2008). For instance, in Glioblastoma  
Multiforme (GBM) a brain tumor involving glial cells have activation of several receptor 
tyrosine kinases (RTKs) and hence targeting any one of these RTKs with available tyrosine 
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kinase inhibitors did not inhibit the tumor growth (Stommel et al. 2007). Imatinib 
(Gleevec™), a small molecule tyrosine kinase inhibitor, that specifically targets a kinase in 
the bcr-abl fusion protein, had a tremendous impact in the treatment of Chronic Myeloid 
Leukemia (CML) (Druker & Lydon 2000). However after promising initial response, the 
patients started to  relapse dramatically and further investigations revealed 17 different point 
mutations in the binding domain of imatinib rendering it ineffective (Shah et al. 2004).  
Since CLL is a disease of multiple deregulated pathways there is need for novel drugs 
which can bind to several signaling pathways to cure the disease. Whether CGP049090 and 
PKF115-584 exhibit this property is worth to be investigated. 
 
5.8 Future Perspectives:  
LEF-1 is a potent transcription factor regulating the expression of several important 
genes. Oncogenic forms of LEF-1 are known to be expressed in both solid and hematological 
malignancies. Colorectal and epithelial cancers express the highest LEF-1 transcripts followed 
by brain and testicular cancers in solid tumors. In hematological malignancies, overall LEF-1 
level was higher in lymphocytic leukemias compared with myeloid leukemias. However, 
acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased 
fraction of the oncogenic LEF-1 compared with chronic lymphocytic leukemia and chronic 
myeloid leukemia (Wang et al. 2005a). The present study resolved LEF-1 to be an effective 
therapeutic target in B-CLL. Hence inhibiting LEF-1 could be an effective therapeutic 
strategy to counter other malignancies with oncogenic LEF-1. 
There is also a need to understand the underlying mechanism governing LEF-1 
overexpression in CLL. The trigger which drives LEF-1 expression in CLL cells but not in 
healthy B cells is yet to be identified. Since LEF-1 is controlled by a negative feedback loop, 
it can be speculated that any mutations in genes involved in the feedback loop (Dickkopf-1, 
LRP) may result in loss of regulation of LEF-1 in CLL cells.  
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Despite acceptable efficacy of CGP049090 and PKF115-584 in vitro and in vivo in the 
present study further pharmacokinetic studies are necessary on the small molecules to 
determine the bioavailability in higher primates. Both CGP049090 and PKF115-584 are 
potential anti-cancer agents in other neoplastic malignancies with aberrant LEF-1/TCF 
transcriptional activity  
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6. Materials & Methods 
6.1. Materials 
6.1.1. Instruments 
 
Equipment       Supplier 
Automatic pipettes    Eppendorf, Germany 
Amaxa Nucleofector device I   Amaxa, Germany 
Balance      Sartorius, Germany    
Cell counting chambers    Neunauer, Germany    
Cell freezing containers    Nalgene, Belgium     
Centrifuge (bench top/4°C)   Eppendorf, Germany    
Centrifuge (cell culture)    Heraeus, Germany    
Electrophoresis system (protein)   Invitrogen, USA 
Electrophoresis System (DNA)   Biorad, USA 
Fluorescent microscope    Olympus, Japan   
Incubators      Thermo Scientific, USA 
Ice machine     Scotsman, USA 
FACS Canto Flow cytometer   BD Bioscience, Germany 
Fridge 4°C & -20°C    Bosch, Germany 
Freezer -80°C     Bosch, Germany    
Heating blocks     Biometra, Germany   
Laminar flow hoods    Heraeus, Germany    
Light Microscopes    Leitz, Germany 
Microtome     Leica, Germany    
pH-meter      InoLab, Germany    
Shaker      IKA, Germany  
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Ultrasonicator     Bandelin Sonoplus, Germany 
Spectrophotometer    Eppendorf, Germany 
Tissue processor     Leica Histokinette, Germany 
Vortex      Bender & Hobein, Germany   
Water bath     GFL, Germany  
Western Blot system  X cell II Blot Module, Invitrogen, USA 
 
6.1.2. Consumables 
 
Consumables      Supplier 
8-12% gradient pre cast gels   Invitrogen, Carlsbad .USA 
Hyperfilm ECL     Kodak,  United Kingdom   
Nitrocellulose membranes   Invitrogen, Carlsbad/USA .USA 
Parafilm      American national Can, IL, USA 
Needles      BD Biosciences, NJ, USA 
Tissue culture material 
 Cryotube vials    Nunc, Roskilde, Denmark 
 Pipette tips, tubes, dishes flasks  Sarstedt, Germany 
 Transwell 96 well plates   Corning Life sciences, MA, USA 
 
6.1.3. Chemical and Reagents 
 
Substance       Supplier 
4x sample buffer     Invitrogen, Carlsbad .USA 
BSA (albumin)     Carl Roth GmbH, Karlsruhe, Germany 
Cremophor-EL     Sigma, Steinheim, Germany  
Materials & Methods 
 
79 
Dithiothreitol (DTT)    Sigma, Steinheim, Germany 
DMEM      Gibco Karlsruhe, Germany 
DMSO      Carl Roth GmbH, Karlsruhe, Germany 
Ethanol      Carl Roth GmbH, Karlsruhe, Germany 
Fetal Calf Serum (FCS)    Gibco Karlsruhe, Germany 
Formaldehyde 4%    Carl Roth GmbH, Karlsruhe, Germany 
Ficoll-hypaque     Amersham Bioscience, Buckinghamshire,  
       UK 
Hydrogen peroxide 3%    Carl Roth GmbH, Karlsruhe, Germany 
Isopropanol     Carl Roth GmbH, Karlsruhe, Germany 
L-15 media     Gibco Karlsruhe, Germany 
Methanol      Carl Roth GmbH, Karlsruhe, Germany 
Non fat dry milk powder    Carl Roth GmbH, Karlsruhe, Germany 
PBS (D-PBS)     Gibco Karlsruhe, Germany 
PBS ( ca & mg free)    Gibco Karlsruhe, Germany 
Penicillin/streptomycin    Gibco Karlsruhe, Germany 
Ponceau S      Sigma, Steinheim Germany 
Protein G beads     Miltenyi Biotec, Bergisch Gladbach, 
Germany 
RPMI-1640     Gibco Karlsruhe, Germany 
SDS PAGE molecular weight standard  Invitrogen, Carlsbad/USA 
Trypsin EDTA     Gibco Karlsruhe, Germany 
Xylene      Carl Roth GmbH, Karlsruhe, Germany 
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6.1.4. Reagent/ Kits 
Annexin V-FITC Apoptosis Detection Kit  BD Biosciences, New Jersy, USA 
Amaxa cell line nucleofection kit V  Amaxa, Cologne, Germany 
CellTiter-GLo® Luminiscent Cell viablity         Promega, Madison, USA 
Assay       
ECL Plus immunoblot detection reagents Amersham Bioscience, New Jersy,USA 
M-PER Mammalian Protein Extraction   Reagent Thermo Fisher Scientific, 
Leicestershire UK. 
Protease Inhibitor cocktail tablets  Roche Applied Science, Mannheim 
Germany 
Phosphatase Inhibitor cocktail tablets   Roche Applied Science, Mannheim 
Germany 
Rossettesep® B cell enrichment kit  Stemcell Technologies, Vancouver, 
Canada  
Vectastain ABC KIT    Vectorlabs, Burlingame, USA 
Vectastain DAB reagent    Vectorlabs, Burlingame ,USA 
Vectashield mounting medium with DAPI Vectorlabs, Burlingame ,USA 
  
6.1.5. Antibodies 
Antibody specificity           Species    Supplier 
 
dephospho β-catenin  Mouse monoclonal  Enzo Life Sciences, NY, USA 
β-catenin   Mouse monoclonal  BD Biosciences, NJ, USA 
β-actin    Mouse monoclonal  BD Biosciences, NJ, USA 
Bcl-2    Mouse monoclonal  BD Biosciences, NJ, USA 
Bid    Rabbit monoclonal    Cell Signaling, MA,  USA 
Caspase 3   Rabbit polyclonal  Cell Signaling, MA, USA 
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Caspase 7   Rabbit polyclonal   Cell Signaling, MA, USA 
Caspase 8   Mouse monoclonal  BD Biosciences, NJ, USA  
Caspase 9   Rabbit polyclonal  Cell Signaling, MA, USA 
c-myc    Rabbit monoclonal  Cell Signaling, MA, USA 
Cyclin D1   Mouse monoclonal  BD Biosciences, NJ, USA 
IgG1 κ isotype control  Mouse monoclonal  Ebiosciences, CA, USA 
LEF-1 (C12A5)  Rabbit monoclonal  Cell Signaling, MA, USA 
LEF-1(REMB1)  Mouse monoclonal  Abcam, MA, USA 
Mcl-1    Rabbit Polyclonal  Santa cruz Biotech, CA, USA 
PARP    Rabbit polyclonal  Cell Signaling, MA, USA 
XIAP    Mouse monoclonal  BD Biosciences, NJ, USA 
 
Secondary Antibodies 
Anti-mouse IgG-HRP Dako cytomation, Glostrup, Denmark 
Anti-rabbit IgG-HRP  Dako cytomation, Glostrup, Denmark 
Anti-mouse IgG-FITC Dako cytomation, Glostrup, Denmark 
Anti-rabbit IgG-FITC  Dako cytomation, Glostrup, Denmark 
 
6.1.6. Inhibitor stock Solutions 
3.3 mM CGP049090 stock solution:  The substance was dissolved in 70% DMSO and 
aliquoted in sterile vials and stored in -20 °C in dark. 
3.3 mM PKF115-584 stock solution:  The substance was dissolved in 70% DMSO and 
aliquoted in sterile vials and stored in -20 °C in dark. 
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6.1.7. Cell lines 
Cell Line Description Source 
JVM-3 Human CLL cells DMSZ, Germany 
MEC-1 Human CLL cells DMSZ, Germany 
HS-5 Human bone marrow 
stromal cells 
DMSZ, Germany 
 
6.2. Methods 
6.2.1. Culture Conditions 
 All the indicated cell lines were cultured at 37°C, relative humidity of 90% and 5% 
CO2. Cell culture media was supplemented with 20% (v/v) heat inactivated Fetal Calf Serum 
(FCS) and 1% penicillin/streptomycin antibiotics. 
 
6.2.2. Culture of primary CLL samples 
6.2.2.1. Isolation of PBMCs by Ficoll gradient 
 Ficoll is a neutral, highly branched, high mass, hydrophilic polysaccharide, which is 
used to separate blood to its components. Peripheral blood mononuclear cells were isolated in 
heparinized blood samples by Ficoll- hypaque plus sedimentation. The samples were diluted 
with PBS in 1:1 ratio and layered on to 20ml of Ficoll and centrifuged at 2300 g for 20 min 
without breaks applied. Mononuclear cells were retrieved from the interface and washed twice 
with PBS and centrifuged at 1200 g for 5 mins. The pellet is thoroughly resuspended and 
cultured in Rosewell’s park memorial institute (RPMI)-1640 medium supplemented with 20% 
(v/v) heat inactivated Fetal Calf Serum (FCS) and 1% antibiotics at 37°C in a humidified 
atmosphere containing 5% CO2. 
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6.2.2.2. Isolation of B-cells by Rosette Sep 
 To obtain pure CLL cells, the Ficoll gradient was preceded by incubation of whole 
blood with Rosette Sep B cell purification antibody cocktail (2 ml of whole blood + 100µl of 
cocktail) at room temperature to aggregate unwanted cells with erythrocytes. 
 
6.2.3. Maintenance of mammalian cells 
6.2.3.1. Culture of suspension cells 
 JVM-3 cells and MEC-1 cells were cultured in RPMI-1640 medium supplemented 
with 10% (v/v) heat inactivated Fetal Calf Serum (FCS) and 1% antibiotics at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were subcultured at confluence every 2-3 
days by dilution of the cells to a concentration of 0.5 x 106 cells/ml. 
 
6.2.3.2. Culture of adherent cells 
 Adherent cell line HS-5 cells were maintained at confluence in Dulbecco’s Modified 
Eagles’s Medium (DMEM) supplemented with 10% (v/v) heat inactivated Fetal Calf Serum 
(FCS) and 1% antibiotics at 37°C in a humidified atmosphere containing 5% CO2. Confluent 
cells were washed two times with PBS and incubated with 2 ml of trypsin/EDTA for 2-3 min 
at 37°C. The cells were later detached and washed with DMEM with 10% FCS and 
centrifuged at 1200 g for 5 min. The pelleted cells are thoroughly resuspended in DMEM with 
10% FCS and diluted to a concentration of 1 x 106 cells/ml. 
 
6.2.3.3. Freezing and thawing cells 
 Cells were grown to confluence and centrifuged at 1200 g for 5 min. They were 
resuspended in freezing medium at a density of 1 x 107 cells/ml. 1 ml aliquots were pipetted 
into cryovials and frozen at -80°C in cell freezing containers. For long time storage the 
cryotubes were transferred to liquid nitrogen tank. 
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Freezing medium 
90%  RPMI-1640 with 20% FCS 
10%  DMSO 
Frozen cells were thawed at 37°C in water bath, and immediately washed in 10 ml fresh 
RPMI-1640 media and centrifuged at 1200 g for 5 min. The cell pellet is resuspended in 
appropriate fresh culture medium  
 
6.2.3.4. Co-culturing cells 
 Co-culturing experiments were performed with HS-5 cell line and with CLL primary 
cells. To obtain a lawn of confluent HS-5 cells, the cells were trypsinized and plated at a 
density of 1 x 105 in 6 well plates with 2 ml DMEM with 10% FCS one day before the 
experiment. On the day of the experiment the cells were washed twice in RPMI with 20% 
FCS and incubated with fresh RPMI with 20% FCS containing primary CLL cells. 
 
6.2.4. Cytotoxcity Assay 
 We carried out cytotoxicity assays in an ATP dependent cell viability assay, CellTiter-
GLo® (Promega) according to manufacturer’s instructions. The CellTiter-Glo® Luminescent 
Cell Viability Assay is a homogeneous method to determine the number of viable cells in 
culture based on quantitation of the ATP present, which signals the presence of metabolically 
active cells (Crouch et al. 1993). This assay relies on the standard luciferase reaction as 
described below. The Luciferase catalyses luciferin in the presence of Adenosinetriphosphate 
(ATP) and Magnesium ions (Mg2+) into luciferyl adenylate and pyrophosphate. This luciferyl 
adenylate in the presence of Oxygen (O2) is converted into oxyluciferin with the release of 
Adenosine monophosphate and light.  
Luciferin + ATP   Luciferyl adenylate + PPi 
Luciferyl adenylate + O2
 
   Oxyluciferin + AMP + Light 
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The assay reagent is a lysis buffer with all the necessary ingredients for luciferase reaction 
except ATP. Once this reagent is added to the culture, the cells are lysed releasing 
intracellular ATP to participate in the luciferase reaction. The amount of luminescent light 
generated is directly proportional to the ATP levels which directly correlate to the number of 
viable cells. The luminescent signal is read by MircoLumatPlus LB96V (Berthhold) 
Luminometer. 
To determine the LC50 values from dose response curves, cells  were seeded in 96-well plates 
at 2x105 cells per well (triplicates) and treated with various concentrations (0.01, 0.1, 1, and 
10 µM) of the inhibitors, DMSO vehicle control ( 0.0002, 0.002, 0.02, 0.2  % v/v) and 
untreated control in a final volume of 100 µl for 24 hours. After incubation 100 µl of the 
CellTiter-GLo® reagent was added to each well and incubated for 10 min at room 
temperature and read on a 96 well plate luminometer at exposure of 1 sec/well.  All the 
experiments were done in triplicates. 
The data was then normalized with the respective vehicle control for each concentration and 
analyzed using non-linear regression using Graphpad Prism 5 (statistical software suite) and 
the LC50 was determined. 
 
6.2.5. Quantification of apoptosis flow cytometry 
 Fluorescence activated cell sorting (FACS) provides a method to study cells based 
upon specific light scattering and fluorescent characteristics of each cell. Expression of 
proteins on the surface or in the cytoplasm can be detected by staining the cells with specific 
fluorescently-labeled antibodies, whereas cells expressing endogenous fluorescent proteins 
can be directly detected. 
The phospholipid phosphatidylserine (PS) is translocated from the inner cytosolic leaflet of 
the plasma membrane bilayer to the outer cell surface, indicating the early events of apoptotic 
machinery. Annexin V is a 35 kDa phospholipid binding protein with high affinity for PS. PS 
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inversion is also a phenomenon during necrosis hence in order to differentiate apoptosis and 
necrosis; Annexin V staining is accompanied with a vita dye Propidium iodide (PI) which 
stains nucleic acid only when the membrane integrity is lost.  
After culture conditions, 5 x 105 cells are washed in PBS and pipetted into FACS tubes. The 
cells are resuspended in 100 µl of 1 X Annexin binding buffer containing 3 µl of annexin-
FITC and 2 µl of PI. The samples were incubated for 20 min at room temperature at dark. 
After 20 min samples were analysed using FACS-Cantor flow cytometer. The percentage of 
Annexin V-/PI- cells (% viable) were compared with untreated cells. 
 
6.2.6. Immunofluorescence  
 Expression of proteins on the surface or in the cytoplasm can be detected by staining 
the cells with specific fluorescently-labeled antibodies this can be detected using standard 
fluorescence microscopy and high resolution images are obtained. Advantage of this 
particular method is that localization studies of proteins of interest can be carried out. 
Immunofluorescence studies were undertaken in primary CLL cells and JVM-3 cell lines to 
visualise the expression and localisation of intracellular proteins. Briefly cells were washed in 
cold RPMI-160 media. Cells were then fixed in 4 % paraformaldehyde for 20 min on ice after 
which washed in twice in PBS supplemented with 1 % BSA. Cells were then permeablized 
with 0.2% saponin in PBS/1%BSA for 5 min followed by a wash in PBS/BSA. They were 
then blocked for 15 min in 5 % normal goat serum (NGS) in PBS/BSA. The cells were 
washed again in PBS/BSA. To this cell suspension primary antibody diluted in PBS/BSA was 
added and incubated at room temperature for 1 hour. This was followed by 3 washes in 
PBS/BSA. After staining with the primary antibody the cells were again blocked in 5% NGS, 
and followed by incubation with the secondary fluorescently labelled antibody diluted in 
PBS/BSA. After washing the cells thrice in PBS/BSA the cells were suspended in 100 µl of 
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VectaShield mounting medium. 15 µl of this cell suspension is spotted on to a glass 
microscopic slide and mounted with a coverslip. The slides are then subjected to fluorescence 
microscopic analysis. 
PBS (Phosphate Buffer): 
1 tablet dissolved in 500 ml of double distilled water (ddH2O). pH adjusted to 7.4 with NaOH 
or HCl 
PBS/BSA Buffer: 
To 100 ml of PBS added 1 gm of Bovine Serum Albumin (BSA) and dissolved. 
0.2% Saponin 
To 10 ml of ddH2O added 200 mg of saponin and vortexed until dissolved. 
 
6.2.7. siRNA mediated gene knockdown 
 Small interfering RNA (siRNA), or silencing RNA, is a class of double-stranded RNA 
molecules, 20-25 nucleotides in length that is involved in the RNA interference (RNAi) 
pathway, where it interferes with the expression of a specific gene. It was first identified as a 
part of post transcriptional gene silencing in plants, but later was shown that synthetic siRNAs 
were to be able to induce RNAi in mammalian cells (Elbashir et al. 2001). 
Synthetic pool of siRNAs targeting different parts of LEF-1 mRNA (ON-TARGET plus 
SMARTpool lef-1 siRNA) or the non-targeting negative control pools (ON-TARGETplus 
siCONTROL) were obtained from Dharmacon, Lafayette, USA. Transfection of siRNAs in 
CLL cells were carried out by Amaxa Nucleofection systems.  
8 x 106 primary CLL cells were resuspended in 100 µl of cell line solution kit V (Amaxa) 
with 0.5 µM of LEF-1 siRNA or non-targeting control siRNAs or Mock transfected without 
siRNAs or Non-transfected with program U-013 using Amaxa nucleofector device I.  
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The cells were immediately transferred in to 6 well plates and co-cultured with HS-5 feeder 
layer in RPMI-1640 supplemented with 20% FCS for 16 hours at 37°C in a CO2 incubator. 
The cell viability was monitored using Annexin V/PI staining by flow cytometry. The 
efficiency of the transfection was enumerated using pmax-GFP plasmid. 
  
6.2.8. Methods in Protein chemistry 
6.2.8.1. Preparation of cell lysates. 
 Cell lysis is the first step in cell fractionation and protein purification by distruption of 
cells either by physical or detergent methods or in combination of both. Detergents and high 
salt concentrations in the buffer break the lipid barrier surrounding the cells. 
Cells were washed twice in ice cold PBS and the cell pellet was slowly resuspended in 200µl 
of M-PER protein extraction reagent supplemented with protease and phosphatase inhibitors 
on ice. The suspension was sonicated for 3 cycles (30 sec/cycle) at 50% power. Then the cell 
extracts were centrifuged at 13000 g at 4°C for 15 min. The clear supernatant was transferred 
into new tubes and used for subsequent western blots or frozen at -80°C for further 
biochemical analysis.  
 
6.2.8.2. Preparation of nuclear and cytoplasmic fractions 
Nuclear and cytoplasmic fractionation was carried using Active motif nuclear extract kit 
according to manufacturer’s instructions. The principle involved is when cells are incubated 
in a hypotonic solution the water diffuses into the cell by osmosis, causing the cells to swell 
and possibly explode. Upon subsequent centrifugation the supernatant contains proteins from 
the cytoplasm alone leaving the nuclear pellet.  Briefly the cells were washed twice in ice cold 
PBS and the cell pellet was resuspended in hypotonic buffer supplemented with protease and 
phosphatase inhibitors for 20 min on ice. 25 µl of detergent is added to the mix and vortexed 
briefly. The cell suspension was later centrifuged at 13000 g for 30 seconds in a 
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microcentrifuge at 4ºC. The supernatant (cytoplasmic fraction) was then transferred into a 
new tube and stored on ice or frozen at -80°C until further analysis. The nuclear pellet was 
washed twice in the hypotonic buffer to rinse of remaining cytoplasmic proteins. The 
resulting nuclear pellet is resuspended in 100-200 µl of MPER protein extraction reagent and 
sonicated for 3 cycles (30 sec/cycle) at 50% power. Then the nuclear extracts were 
centrifuged at 13000 g at 4°C for 15 min. The clear supernatant (nuclear fraction) was 
transferred into new tubes and used for western blots or frozen at -80°C for further analysis. 
 
6.2.8.3. Quantification of proteins 
 For the quantification of proteins, the BCA (Bicinchoninic acid) protein assay reagent 
kit from Pierce, USA was employed. The principle involved in BCA assay is the formation of 
a Cu2+ protein complex in alkaline conditions, followed by reduction of the Cu2+ to Cu1+. The 
amount of reduction is proportional to the protein present in the lysates. Two molecules of 
BCA chelate with one molecule of Cu1+ to form a purple-blue complex which can be 
monitored at its absorbance maximum of 562 nm. 
For this assay 2 µl of protein lysates were used and diluted in 98 µl of distilled water. To 
prepare protein standards for calibration, 0, 5, 10, 15, 20 µg of bovine serum albumin (BSA) 
from 2 mg/ml stock solution was diluted in water to a final volume of 100 µl. working BCA 
reagents were freshly prepared by mixing reagent A and reagent B from the assay kit in 1:50 
(v/v) ratio. The protein samples were diluted with 900 µl of working reagent mixture and the 
components were mixed with inversion. The reaction tubes were incubated for 10 min and 
samples were measured at 562 nm absorbance using a spectrophotometer. A standard curve of 
absorbance versus micrograms protein was plotted and the protein concentration in each 
sample was determined by linear regression. 
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6.2.8.4. Co-immunoprecipitation 
 Co-immunoprecipitation (Co-IP) is best preceded by a discussion of 
immunoprecipitation (IP) to help understanding of the principles involved. 
Immunoprecipitation (IP) involves the enrichment or separation of specific proteins from the 
cellular lysates by using specific antibodies. The immune complexes are then precipitated 
using immobilized protein A or protein G, bacterial proteins which have high affinity to the 
Fc part of the immunoglobulin which are covalently linked to agarose or magnetic beads. The 
process of capturing this complex from the solution is referred to as precipitation. Finally, 
components of the bound immune complex (both antigen and antibody) are eluted from the 
support and analyzed by SDS-PAGE often followed by western blot detection to verify the 
identity of the antigen. Co-immunoprecipitation (Co-IP) is an extension of IP except the fact 
that the precipitated protein has some interaction partners complexed to it de novo and will be 
useful to study protein interactions. This is only an assumption, however, that is subject to 
further verification. 
 For Co-IP experiments we used µMACS™ Protein A/G Kits from Miltenyi Biotec, 
Bergisch Gladbach Germany. Immunoprecipitation with µMACS Protein A/G MicroBeads 
involves a short incubation of cleared lysate with the MicroBeads coated with the specific 
antibody the magnetizable immune complex is passed over a separation column placed in the 
magnetic field of a MACS Separator. The labeled complex is retained within the column 
while other proteins are efficiently washed away. For SDS-PAGE analysis, the 
immunoprecipitated protein is eluted from the column with SDS gel loading buffer. 
For Co-IP 500 µg of total protein extracts were incubated 10 µM of CGP049090 or PKF115-
584 or 0.02% DMSO (vehicle control) for 16 hours. Later this extract 2 µg of precipitating 
antibody and 50 µl of µMACS Protein G beads were added and incubated overnight to 
magnetically label the immune complexes. The immune complexes were then passed through 
a µ separation column in a magnetic field. The column was rinsed 3 times with 200 µl of high 
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salt buffer (M-PER lysis buffer) which washes off unspecific and un-complexed proteins but 
retains the magnetically labeled immune complexes. 20 µl of pre-heated hot SDS sample 
buffer was added to the column and incubated for 5 min in room temperature. Later 40 µl of 
pre-heated SDS sample buffer was added to elute the immune complexes. The eluate was 
stored and later analyzed by western blotting. 
 
1X SDS Sample Buffer:  
4X NuPAGE SDS sample buffer:  25 µl 
NuPAGE reducing agent (DTT): 10 µl 
DdH2O:    65 µl  
Total:     100µl 
 
6.2.8.5. SDS PAGE ELECTROPHORESIS 
 In SDS polyacrylamide gel electrophoresis (SDS-PAGE), proteins are separated on the 
basis of molecular weight of the proteins. Two sequential gels are cast: the stacking gel which 
is slightly acidic with low polyacrylamide concentration and the separating gel which is more 
basic and higher polyacrylamide content which allows proteins to be separated according to 
their molecular sizes, where smaller proteins travel faster than larger proteins. 
SDS is an anionic detergent which denatures the protein and imparts negative charge, and in 
an electric field the protein is attracted towards the anode and they are resolved solely on the 
basis of their sizes by the pores of the polyacrylamide gel. 
 In this study we used NuPAGE® 4-12% Bis-Tris gradient gels, NuPAGE® MES Running 
buffer, NuPAGE® LDS sample Buffer and NuPAGE® Sample reducing agent and 
NuPAGE® Antioxidant from Invitrogen. The SDS PAGE was carried out in a vertical Xcell 
surelock apparatus according to manufacturer’s instructions. 
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6.2.8.6. Protein transfer (Western Blot) 
 For the detection of protein of interest, the resolved bands on the gel are transferred 
blotting membranes by the process referred to as blotting. This blotting process was achieved 
using Xcell blot module (Invitrogen) according to manufacturer’s instructions. The proteins 
are transferred onto nitrocellulose membranes in the NuPAGE® Transfer buffer at 35V for 60 
min. Membranes, filter paper, fiber pads, were all pre-soaked in the transfer buffer.  
The following is the order of assembly in the blot module: 
Anode (Red) 
Fiber pad 
Filter paper 
Membrane 
Gel 
Filter paper 
Fiber pad 
Cathode (Black) 
Care should be taken to remove all bubbles in the assembly. The transfer the efficiency of the 
western blot is monitored by staining the nitrocellulose membrane in Ponceu-S solution for 5 
min. The membrane is destained using 0.1 M NaOH sodium hydroxide solution in ddH2O. 
0.1M NaOH 
4 grams of NaOH dissolved in 1 L of ddH2O. 
 
Ponceau-S stock Solution (100 ml) 
2% m/v Ponceau S 
30% m/v Trichloroacetic acid 
30% m/v  Sulphuric acid 
The stain is dissolved in 100 ml of ddH2O. The working solution is made by diluting the 
stock solution 3 times with ddH2O. 
6.2.8.7. Immunoblot 
 Immunoblotting involves the detection of specific proteins on membranes using 
antibodies. The membranes are first blocked with blocking agents to prevent unspecific 
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binding of antibodies. Then, primary antibodies that recognize specific proteins or tags on 
proteins are allowed to bind to their targets. After washing to remove non-specific binding 
and excess antibody, the secondary antibodies coupled with Horse Radish Peroxidase (HRP) 
recognize the primary antibodies. After washes the enzymes are detected using 
chemiluminiscence 
After the proteins are transferred to the nitrocellulose membranes, the blots are blocked in 
Block I solution at room temperature for 1 hour. Subsequently the membranes are incubated 
overnight with respective primary antibody in a horizontal roller at 4°C. The membranes are 
then washed 3 x 10 min cycles in 50 ml PBS in a horizontal shaker. This is followed by 
incubation of the membranes in Block II solution with HRP conjugated secondary antibody 
for 1 hour at room temperature on a roller. Thereafter the membranes are washed 3 x 10 min 
cycles in 50 ml PBS in a horizontal shaker before the detection of proteins using the ECL 
detection reagents. 
For detection of proteins by chemiluminiscence, 1 ml of fresh solution mixture was made by 
mixing Solution A & Solution B in a ration 1:1 (v/v). This mixture is immediately spread on 
the membrane and incubated for 1 min. The excess solution is drained off and the membrane 
is exposed to hyperfilm in dark for appropriated time and developed in X-ray film processor. 
 
Block I solution (PBS) 
5% milk powder 
10% Rotiblock® 
 
 
Block II solution (PBS) 
5% milk powder 
PBS (Phosphate Buffer) 
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1 tablet dissolved in 500 ml of ddH2O. pH adjusted to 7.4 with NaOH or HCl 
6.2.9. Generation of JVM-3 Xenograft Subcutaneous Tumor Mouse Model 
 During molecular target therapies for cancer, some relevant and novel aspects from the 
clinical setting should be considered for the in vivo experimental studies aimed at the 
development of new therapeutic strategies. The preclinical development of new drugs or 
combination of drugs with molecular targets should be planned with a modern approach based 
firstly on the use of advanced animal models.  
We carried out in vivo studies in JVM-3 subcutaneous xenografts in athymic nude mice as 
described previously(Loisel et al. 2005) . The nude mice were developed from the transfer of 
the nude gene (FOXN1) from Crl:NU-Foxn1nu to a CD-1 mouse through a series of crosses 
and backcrosses at Charles River Laboratories™. The animal lacks a thymus, is unable to 
produce T-cells, and is therefore immunodeficient. Hence the animal can graft any 
human/mouse transplanted tissue. This mouse is usually employed in pre-clinical drug 
development 
 
CGP049090 and PKF115-584 Stock Solution for in vivo studies: 
 
 Both small molecules are extremely lipophilic and hence required stable yet non-toxic 
excipient for in vivo application. The drug was dissolved first dissolved in 1 part 100% 
ethanol followed by 1 part of cremophor EL and 9 parts of ddH2O. The final suspension 
(6.25mg/ml) is vortexed vigorously before intraperitoneal injection. 
 
Mice were allowed 3 days acclimatization period in the local animal facility upon arrival. 
The mice were then pre treated with 3Gy of whole body irradiation 1 day prior to inoculation 
as this enhances tumor engraftment dramatically by depleting residual B or T cells. JVM-3 
cells are grown in complete RPMI-1640 with 10% FCS and harvested at 75-80 % confluency. 
Cells are washed in PBS resuspend them in L-15 media without FCS and antibiotics at 1x107 
in 100µl. Cells are then injected subcutaneously (SC) in the nude mice under aseptic 
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conditions using 1 cm3 syringe and a 19 gauge needle. The mice are observed for 2 weeks for 
tumour progression. Tumor volume is measured once it’s palpable using the formula. The 
mice are then randomized into treated and vehicle control groups provided that both groups 
have the same tumor volume before initiation of therapy. The therapy is initiated once the 
tumor volume of the groups is around 90-100 mm3. The mice are divided into three groups; 
Vehicle control, CGP049090 group and PKF115-584 group (n= 8 mice/group) and drug was 
administered at 25mg/kg body weight for 12 days intraperitoneally. The tumor volume and 
body weight is measured every third day after initiation of therapy in both control and treated 
group. Due to ethical reasons the maximal tumor volume in the mice will not be allowed to 
exceed 1000 mm3. If it exceeds, the mouse was sacrificed and declared dead on that particular 
day. 
 
6.2.9.1. Evaluation of in vivo antitumor activity 
Tumor volume (TV) was measured prior to therapy and every third day after initiation of 
therapy as described previously (Kawato et al. 1991).  
TV was calculated according to the formula  
TV (mm3) = L (mm) x W (mm) x H (mm) /2,  
L is the tumor length  
W is the tumor width 
H is tumor height. 
 
 
 The inhibition rate (IR) of tumor growth on the basis of TV was calculated according to the 
formula  
IR = (l - RVt/RVc) x 100%,  
 RVt represents the mean ratio of TV on day n to TV on day 0 of a treated group  
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RVc indicates the ratio of the control group.  
Largest value for IR was designated as IRmax which indicates the greatest effect of each 
tested inhibitor 
The rate of body weight reduction (∆BW) was calculated according to the following formula: 
  BW = (1 - BWn / BWo) x 100% 
 BWn represents the mean body weight of mice on day n  
BW0 represented the mean body weight on day 0.  
The maximum value for ∆BW was designated as ∆BWmax; from which each test compound’s 
toxicity to mice was evaluated. 
 
6.2.10. Histochemistry  
Histochemistry involves the process in which a tissue is sliced into very thin sections, 
which can be either stained by certain dyes to study the cell morphology or using specific 
antibodies (immunohistochemistry) to localise proteins of interest. This procedure involves 
fixation, dehydration, paraffin embedment and subsequent sectioning with a microtome. 
Fixation: 
After euthanization of the mouse the tumor is dissected and sliced into sizes of 1 cm3. These 
slices are immediately fixed in 4 % formaldehyde for 24 hours. This step leads to cross-
linking of proteins in the tumor specimens thereby preserving the structural integrity of the 
cells. This step is done in an automatic tissue processor (Leica™ Histokinette) 
 
 
Dehydration: 
Formaldehyde and water are known to interfere with several downstream staining process, 
hence formaldehyde and remaining water is completely removed from the tissue by 
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incubating the tumor specimen in successive series of increasing concentrations of ethanol 
(30%, 50%, 70%, 80%, 90%, 95%, and 100%) for two hours each by the tissue processor. 
Paraffin embedment: 
The specimens are incubated in a clearing solution usually xylol which is totally miscible with 
the dehydrating alcohol and wax embedding agent for 2 hours. Later the tissue is impregnated 
with paraffin at 65°C for 4 hours for the final embedding stage which sets specimens in 
blocks of paraffin wax from which sections may be cut. 
Sectioning: 
The embedded tissue blocks are cooled on a cold plate and mounted onto a standard 
microtome and sections of 10 µm are made. These sections are then floated onto a warm 
water bath to smooth out the creases and then lifted out onto a glass microscope slide and 
allowed to dry on a hot plate set just below the melting point of the wax. Once the sections are 
dried onto the slide they are ready for immunohistochemistry analysis. 
 
6.2.11. Immunohistochemistry 
 Immunohistochemistry is a useful tool to identify key changes in cellular behavior 
after a therapeutic intervention in vivo. This technique involves treating a part of a tumor 
section with antibodies that recognize cell proteins of interest. The method involves 
establishing a biotin link, through avidin, between the horseradish peroxidase enzyme and a 
secondary antibody reagent, enzyme localization can be achieved at the site of primary 
antibody interaction with the specimen. 
The tumor sections embedded in paraffin are incubated in three washes of xylene for 5 min 
each to deparaffinze the section. Later the sections are rehydrated with decreasing 
concentration of ethanol (100% 95% 75%) 10 min each. After rinsing the slides in ddH2O, 
the slides are placed in antigen unmasking buffer (TE buffer) and boiled for 20 min. After 
cooling them down for 5 min the slides are washed in ddH2O and incubated in 3% hydrogen 
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peroxide for 10 min. The sections are then washed in ddH2O and blocked in 500 µl of 
blocking solution for 1 hour. After removing the blocking solution 500µl of primary antibody 
diluted in the antibody diluent to each is added to the sections and incubated overnight at 4°C 
in a humidified chamber.  
The next day the sections are rinsed in wash buffer three times for 5 min, followed by 
incubation with 500 µl of biotinylated secondary antibody, diluted in TBST and incubated in 
room temperature for 1 hour. The slides are washed again three times for 5 min and 500 µl of 
(The Avidin-Biotin Complex) ABC reagent is added to the sections and incubated for 1 hour. 
The sections are washed in wash buffer thrice and 200 µl of 3,3'-Diaminobenzidine (DAB) 
substrate is added to each section and incubated for 20 min until the appropriate color reaction 
develops. The sections are washed in ddH2O and mounted with coverslips and observed 
under documented with the light microscope. 
 
Wash Buffer 
10X Tris Buffered Saline (TBS): 24.2 g Tris base (C4H11NO3) and 80 g sodium chloride 
(NaCl) to 1 L ddH2O. pH adjusted to 7.6 with concentrated HCl. 
1X TBS/0.1% Tween-20 (1X TBST): 100 ml 10X TBS to 900 ml dH2O and 1  ml Tween-20 
and mix. 
Antibody diluent /Blocking solution  
TBST/5% normal goat serum 
Antigen unmasking buffer  
TE Buffer: 10 mM Tris/1 mM EDTA/0.05% Tween–20, pH 9.0: To prepare 1litre add 1.21 g 
Tris base (C4H11NO3) and 0.372 g EDTA (C10H14N2O8Na2•2H2O) to 950 ml ddH2O. Adjust 
pH to 9.0, add 0.5 ml Tween–20, then adjust final volume to 1000 ml with ddH2O. 
3% Hydrogen peroxide 
 10 ml of 30% H2O2 to 90 ml ddH2O. 
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ABC Reagent and DAB Substrate 
 (Vectastain ABC Kit, vector laboratories, Burlingame, CA) 
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